Elevance Health (ELV) 10-Q19 Oct 222022 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information Document - shares	9 Months Ended
Document And Entity Information Document - shares	Sep. 30, 2022	Oct. 12, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001156039
Entity File Number	001-16751
Entity Registrant Name	ELEVANCE HEALTH, INC.
Entity Incorporation, State or Country Code	IN
Entity Tax Identification Number	35-2145715
Entity Address, Address Line One	220 Virginia Avenue
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46204
City Area Code	833
Local Phone Number	401-1577
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ELV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		238,827,582

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 8,872	$ 4,880
Fixed maturities, current	25,526	26,267
Equity securities	1,503	1,881
Premium receivables	6,682	5,681
Self-funded receivables	3,873	4,010
Other receivables	3,651	3,749
Other current assets	5,496	4,654
Total current assets	55,603	51,122
Long-term investments:
Fixed maturities, long-term	622	632
Other invested assets	5,516	5,225
Property and equipment, net	4,197	3,919
Goodwill	24,381	24,228
Other intangible assets	10,536	10,615
Other noncurrent assets	2,171	1,719
Total assets	103,026	97,460
Current Liabilities:
Medical claims payable	15,242	13,518
Other policyholder liabilities	5,482	5,521
Unearned income	3,702	1,153
Accounts payable and accrued expenses	4,963	4,970
Short-term borrowings	265	275
Current portion of long-term debt	2,249	1,599
Other current liabilities	9,384	7,849
Total current liabilities	41,287	34,885
Long-term debt, less current portion	21,258	21,157
Reserves for future policy benefits, noncurrent	825	802
Deferred tax liabilities, net	1,825	2,805
Other noncurrent liabilities	1,788	1,683
Total liabilities	66,983	61,332
Commitments and contingencies – Note 11
Shareholders' equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none	0	0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 238,974,624 and 241,770,746	2	2
Additional paid-in capital	9,169	9,148
Retained earnings	29,604	27,088
Accumulated other comprehensive loss	(2,784)	(178)
Total shareholders' equity	35,991	36,060
Noncontrolling interests	52	68
Total equity	36,043	36,128
Total liabilities and shareholders' equity	$ 103,026	$ 97,460

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Fixed maturities, amortized cost, current	$ 28,306	$ 25,641
Fixed maturities, allowance for credit loss, current	10	6
Fixed Maturities, long-term, amortized cost	671	616
Fixed maturities, allowance for credit Loss, noncurrent	$ 0	$ 0
Preferred stock, par value	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	238,974,624	241,770,746
Common stock, shares outstanding	238,974,624	241,770,746
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements Of Inco

Consolidated Statements Of Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Consolidated Statements Of Income - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Premiums	$ 33,722	$ 30,395	$ 99,583	$ 86,604
Product revenue	3,972	3,353	10,841	9,132
Administrative fees and other revenue	1,931	1,800	5,569	5,189
Total operating revenue	39,625	35,548	115,993	100,925
Net investment income	371	335	1,112	1,026
Net (losses) gains on financial instruments	(57)	(61)	(439)	107
Total revenues	39,939	35,822	116,666	102,058
Expenses
Benefit expense	29,404	26,645	86,396	75,107
Cost of products sold	3,437	2,898	9,389	7,825
Selling, general and administrative expense	4,514	3,946	13,124	11,692
Interest expense	213	201	622	598
Amortization of other intangible assets	225	136	520	306
Loss on extinguishment of debt	0	0	0	5
Total expenses	37,793	33,826	110,051	95,533
Income before income tax expense	2,146	1,996	6,615	6,525
Income tax expense	533	494	1,557	1,555
Net income	1,613	1,502	5,058	4,970
Net loss (income) attributable to noncontrolling interests	5	7	18	(3)
Shareholders’ net income	$ 1,618	$ 1,509	$ 5,076	$ 4,967
Shareholders’ net income per share
Basic net income per share	$ 6.75	$ 6.20	$ 21.11	$ 20.33
Diluted net income per share	6.68	6.13	20.86	20.09
Dividends per share	$ 1.28	$ 1.13	$ 3.84	$ 3.39

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 1,613	$ 1,502	$ 5,058	$ 4,970
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments	(639)	(97)	(2,630)	(284)
Change in non-credit component of impairment losses on investments	(1)	(1)	(3)	1
Change in net unrealized gains/losses on cash flow hedges	2	4	8	10
Change in net periodic pension and postretirement costs	7	8	23	26
Foreign currency translation adjustments	(7)	(1)	(15)	(7)
Other comprehensive loss	(638)	(87)	(2,617)	(254)
Net loss (income) attributable to noncontrolling interests	5	7	18	(3)
Other comprehensive loss attributable to noncontrolling interests	3	1	11	1
Total shareholders’ comprehensive income	$ 983	$ 1,423	$ 2,470	$ 4,714

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net income	$ 5,058	$ 4,970
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses (gains) on financial instruments	439	(107)
Equity in net earnings of other invested assets	(304)	(437)
Depreciation and amortization	1,202	942
Deferred income taxes	(170)	114
Share-based compensation	191	196
Changes in operating assets and liabilities:
Receivables, net	(678)	(1,751)
Other invested assets	46	(56)
Other assets	(474)	(470)
Policy liabilities	1,537	2,328
Unearned income	2,548	(308)
Accounts payable and other liabilities	598	1,093
Income taxes	(41)	168
Other, net	(35)	10
Net cash provided by operating activities	9,917	6,692
Investing activities
Purchases of investments	(19,612)	(15,130)
Proceeds from sale of investments	9,402	8,339
Maturities, calls and redemptions from investments	7,606	3,388
Changes in securities lending collateral	(677)	(1,030)
Purchases of subsidiaries, net of cash acquired	(623)	(3,442)
Purchases of property and equipment	(854)	(747)
Other, net	(91)	(50)
Net cash used in investing activities	(4,849)	(8,672)
Financing activities
Net proceeds from (repayments of) commercial paper borrowings	375	(150)
Proceeds from long-term borrowings	1,286	3,462
Repayments of long-term borrowings	(982)	(954)
Proceeds from short-term borrowings	1,365	175
Repayments of short-term borrowings	(1,375)	0
Changes in securities lending payable	685	1,030
Changes in bank overdrafts	181	316
Repurchase and retirement of common stock	(1,748)	(1,378)
Cash dividends	(924)	(831)
Proceeds from issuance of common stock under employee stock plans	152	161
Taxes paid through withholding of common stock under employee stock plans	(91)	(101)
Other, net	16	8
Net cash (used in) provided by financing activities	(1,060)	1,738
Effect of foreign exchange rates on cash and cash equivalents	(16)	(9)
Change in cash and cash equivalents	3,992	(251)
Cash and cash equivalents at beginning of period	4,880	5,741
Cash and cash equivalents at end of period	$ 8,872	$ 5,490

Consolidated Statements Of Chan

Consolidated Statements Of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive (Loss) Income [Member]	Noncontrolling Interest [Member]
Balance (in shares), Beginning at Dec. 31, 2020				245.4
Total shareholders' equity, Beginning Balance at Dec. 31, 2020				$ 3	$ 9,244			$ 23,802	$ 150
Noncontrolling interests, Beginning Balance at Dec. 31, 2020										$ 0
Total equity, Beginning Balance at Dec. 31, 2020			$ 33,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						$ 1,665
Net Income (Loss) Attributable to Noncontrolling Interest										2
Net income	$ 1,667
Shareholders' other comprehensive income (loss)									(345)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										(2)
Other Comprehensive Income (Loss), Net of Tax	(347)
Noncontrolling interests adjustment	65									65
Repurchase and retirement of common stock, shares				(1.4)
Repurchase and retirement of common stock	(447)			$ (1)	(53)	(393)
Dividends and dividend equivalents	(281)					(281)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.9
Issuance of common stock under employee stock plans, net of related tax benefits	62				62
Balance (in shares), Ending at Mar. 31, 2021				244.9
Total shareholders' equity, Ending Balance at Mar. 31, 2021				$ 2	9,253	24,793			(195)
Noncontrolling interests, Ending Balance at Mar. 31, 2021										65
Total equity, Ending Balance at Mar. 31, 2021	33,918
Balance (in shares), Beginning at Dec. 31, 2020				245.4
Total shareholders' equity, Beginning Balance at Dec. 31, 2020				$ 3	9,244			23,802	150
Noncontrolling interests, Beginning Balance at Dec. 31, 2020										0
Total equity, Beginning Balance at Dec. 31, 2020			33,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	4,967
Net Income (Loss) Attributable to Noncontrolling Interest	3
Net income	4,970
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(1)
Other Comprehensive Income (Loss), Net of Tax	$ (254)
Repurchase and retirement of common stock, shares	(3.9)
Repurchase and retirement of common stock	$ (1,378)
Balance (in shares), Ending at Sep. 30, 2021				242.8
Total shareholders' equity, Ending Balance at Sep. 30, 2021	35,808			$ 2	9,138	26,700			(103)
Noncontrolling interests, Ending Balance at Sep. 30, 2021										71
Balance (in shares), Beginning at Mar. 31, 2021				244.9
Total shareholders' equity, Beginning Balance at Mar. 31, 2021				$ 2	9,253	24,793			(195)
Noncontrolling interests, Beginning Balance at Mar. 31, 2021										65
Total equity, Beginning Balance at Mar. 31, 2021	33,918
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						1,793
Net Income (Loss) Attributable to Noncontrolling Interest										8
Net income	1,801
Shareholders' other comprehensive income (loss)									178
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										2
Other Comprehensive Income (Loss), Net of Tax	180
Noncontrolling interests adjustment	3									3
Repurchase and retirement of common stock, shares				(1.3)
Repurchase and retirement of common stock	(480)			$ 0	(47)	(433)
Dividends and dividend equivalents	(279)					(279)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.3
Issuance of common stock under employee stock plans, net of related tax benefits	119				119
Convertible debenture repurchases, conversions and tax adjustments	(216)				(216)
Balance (in shares), Ending at Jun. 30, 2021				243.9
Total shareholders' equity, Ending Balance at Jun. 30, 2021				$ 2	9,109	25,874			(17)
Noncontrolling interests, Ending Balance at Jun. 30, 2021										78
Total equity, Ending Balance at Jun. 30, 2021	35,046
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	1,509					1,509
Net Income (Loss) Attributable to Noncontrolling Interest	(7)									(7)
Net income	1,502
Shareholders' other comprehensive income (loss)									(86)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(1)									(1)
Other Comprehensive Income (Loss), Net of Tax	(87)
Noncontrolling interests adjustment	1									1
Repurchase and retirement of common stock, shares				(1.2)
Repurchase and retirement of common stock	(451)			$ 0	(44)	(407)
Dividends and dividend equivalents	(276)					(276)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.1
Issuance of common stock under employee stock plans, net of related tax benefits	75				75
Convertible debenture repurchases, conversions and tax adjustments	(2)				(2)
Balance (in shares), Ending at Sep. 30, 2021				242.8
Total shareholders' equity, Ending Balance at Sep. 30, 2021	35,808			$ 2	9,138	26,700			(103)
Noncontrolling interests, Ending Balance at Sep. 30, 2021										71
Balance (in shares), Beginning at Dec. 31, 2021				241.8
Total shareholders' equity, Beginning Balance at Dec. 31, 2021	36,060			$ 2	9,148	27,088		27,065	(178)
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021							$ (23)
Noncontrolling interests, Beginning Balance at Dec. 31, 2021	68									68
Total equity, Beginning Balance at Dec. 31, 2021	36,128		36,105
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		$ (23)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						1,805
Net Income (Loss) Attributable to Noncontrolling Interest										(10)
Net income	1,795
Shareholders' other comprehensive income (loss)									(1,058)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										(5)
Other Comprehensive Income (Loss), Net of Tax	(1,063)
Noncontrolling interests adjustment	3									3
Repurchase and retirement of common stock, shares				(1.2)
Repurchase and retirement of common stock	(545)				(45)	(500)
Dividends and dividend equivalents	(312)					(312)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.5
Issuance of common stock under employee stock plans, net of related tax benefits	39				39
Convertible debenture repurchases, conversions and tax adjustments	9				9
Balance (in shares), Ending at Mar. 31, 2022				241.1
Total shareholders' equity, Ending Balance at Mar. 31, 2022				$ 2	9,151	28,058			(1,236)
Noncontrolling interests, Ending Balance at Mar. 31, 2022										56
Total equity, Ending Balance at Mar. 31, 2022	36,031
Balance (in shares), Beginning at Dec. 31, 2021				241.8
Total shareholders' equity, Beginning Balance at Dec. 31, 2021	36,060			$ 2	9,148	27,088		$ 27,065	(178)
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021							$ (23)
Noncontrolling interests, Beginning Balance at Dec. 31, 2021	68									68
Total equity, Beginning Balance at Dec. 31, 2021	36,128		$ 36,105
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		$ (23)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	5,076
Net Income (Loss) Attributable to Noncontrolling Interest	(18)
Net income	5,058
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(11)
Other Comprehensive Income (Loss), Net of Tax	$ (2,617)
Repurchase and retirement of common stock, shares	(3.7)
Repurchase and retirement of common stock	$ (1,748)
Balance (in shares), Ending at Sep. 30, 2022				239
Total shareholders' equity, Ending Balance at Sep. 30, 2022	35,991			$ 2	9,169	29,604			(2,784)
Noncontrolling interests, Ending Balance at Sep. 30, 2022	52									52
Total equity, Ending Balance at Sep. 30, 2022	36,043
Balance (in shares), Beginning at Mar. 31, 2022				241.1
Total shareholders' equity, Beginning Balance at Mar. 31, 2022				$ 2	9,151	28,058			(1,236)
Noncontrolling interests, Beginning Balance at Mar. 31, 2022										56
Total equity, Beginning Balance at Mar. 31, 2022	36,031
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income						1,653
Net Income (Loss) Attributable to Noncontrolling Interest										(3)
Net income	1,650
Shareholders' other comprehensive income (loss)									(913)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest										(3)
Other Comprehensive Income (Loss), Net of Tax	(916)
Noncontrolling interests adjustment	5									5
Repurchase and retirement of common stock, shares				(1.3)
Repurchase and retirement of common stock	(624)				(48)	(576)
Dividends and dividend equivalents	(310)					(310)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.2
Issuance of common stock under employee stock plans, net of related tax benefits	111				111
Convertible debenture repurchases, conversions and tax adjustments	(80)				(80)
Balance (in shares), Ending at Jun. 30, 2022				240
Total shareholders' equity, Ending Balance at Jun. 30, 2022				$ 2	9,134	28,825			(2,149)
Noncontrolling interests, Ending Balance at Jun. 30, 2022										55
Total equity, Ending Balance at Jun. 30, 2022	35,867
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' net income	1,618					1,618
Net Income (Loss) Attributable to Noncontrolling Interest	(5)									(5)
Net income	1,613
Shareholders' other comprehensive income (loss)									(635)
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest	(3)									(3)
Other Comprehensive Income (Loss), Net of Tax	(638)
Noncontrolling interests adjustment	5
Noncontrolling interests adjustment										5
Repurchase and retirement of common stock, shares				(1.2)
Repurchase and retirement of common stock	(579)				(47)	(532)
Dividends and dividend equivalents	(307)					(307)
Issuance of common stock under employee stock plans, net of related tax benefits, Shares				0.2
Issuance of common stock under employee stock plans, net of related tax benefits	103				103
Convertible debenture repurchases, conversions and tax adjustments	(21)				(21)
Balance (in shares), Ending at Sep. 30, 2022				239
Total shareholders' equity, Ending Balance at Sep. 30, 2022	35,991			$ 2	$ 9,169	$ 29,604			$ (2,784)
Noncontrolling interests, Ending Balance at Sep. 30, 2022	52									$ 52
Total equity, Ending Balance at Sep. 30, 2022	$ 36,043

Organization

Organization	9 Months Ended
Organization	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires. Elevance Health is a health company with the purpose of improving the health of humanity. We are the largest health insurer in the United States in terms of medical membership, serving over 47 million medical members through our affiliated health plans as of September 30, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Integra Managed Care, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. As part of our name change to Elevance Health, on June 15, 2022 we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands: • Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans; • Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and • Carelon — this brand will bring together our healthcare brands and capabilities, including our Diversified Business Group and IngenioRx business under a single brand name. We now refer to our Diversified Business Group as Carelon. In January 2023, IngenioRx will become CarelonRx. There are currently no segment changes associated with this branding strategy. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future.

Basis Of Presentation and Signi

Basis Of Presentation and Significant Accounting Policies	9 Months Ended
Basis Of Presentation and Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K. Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income. Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets. Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default. For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income. The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets. We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets. Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments. Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts. Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively. Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively. Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively. Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material. Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) . The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures. There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.

Business Acquisitions

Business Acquisitions	9 Months Ended
Business Acquisitions	Sep. 30, 2022
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions Completed Acquisitions On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”) from Personal Touch Holding Corporation. Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase price was allocated to the tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $123 to goodwill, including measurement period adjustments to goodwill of $13 during the quarter ended September 30, 2022. The majority of goodwill is deductible for income tax purposes. As of September 30, 2022, the initial accounting for the acquisition had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.

Business Optimization Initiativ

Business Optimization Initiatives	9 Months Ended
Business Optimization Initiatives	Sep. 30, 2022
Business Optimization Initiatives [Abstract]
Business Optimization Initiatives	Business Optimization Initiatives Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020. Commercial & Specialty Business Government Business IngenioRx Other Total 2020 Business Optimization Initiatives Employee termination costs: Liability for employee termination costs at January 1, 2022 $ 61 $ 57 $ 1 $ 3 $ 122 Payments (16) (14) — — (30) Liability for employee termination costs at September 30, 2022 $ 45 $ 43 $ 1 $ 3 $ 92

Investments

Investments	9 Months Ended
Investments	Sep. 30, 2022
Investments [Abstract]
Investments	Investments Fixed Maturity Securities We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods. A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows: Cost or Amortized Cost Gross Gross Allowance Estimated September 30, 2022 Fixed maturity securities: United States Government securities $ 1,673 $ — $ (125) $ — $ 1,548 Government sponsored securities 65 — (4) — 61 Foreign government securities 322 — (70) (1) 251 States, municipalities and political subdivisions 4,431 5 (355) — 4,081 Corporate securities 13,766 9 (1,560) (7) 12,208 Residential mortgage-backed securities 4,748 7 (506) (2) 4,247 Commercial mortgage-backed securities 77 — (7) — 70 Other securities 3,895 37 (250) — 3,682 Total fixed maturity securities $ 28,977 $ 58 $ (2,877) $ (10) $ 26,148 December 31, 2021 Fixed maturity securities: United States Government securities $ 1,443 $ 7 $ (18) $ — $ 1,432 Government sponsored securities 65 4 (1) — 68 Foreign government securities 353 7 (13) — 347 States, municipalities and political subdivisions 5,321 310 (10) — 5,621 Corporate securities 12,044 401 (78) (4) 12,363 Residential mortgage-backed securities 4,059 75 (35) (2) 4,097 Commercial mortgage-backed securities 65 2 (3) — 64 Other securities 2,907 24 (24) — 2,907 Total fixed maturity securities $ 26,257 $ 830 $ (182) $ (6) $ 26,899 For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: Less than 12 Months 12 Months or Greater (Securities are whole amounts) Number of Estimated Gross Number of Estimated Gross September 30, 2022 Fixed maturity securities: United States Government securities 65 $ 911 $ (77) 29 $ 303 $ (48) Government sponsored securities 40 61 (4) 1 — — Foreign government securities 225 169 (34) 151 81 (36) States, municipalities and political subdivisions 1,964 3,602 (314) 139 200 (41) Corporate securities 4,322 10,228 (1,165) 1,318 1,679 (395) Residential mortgage-backed securities 2,035 2,949 (294) 530 1,182 (212) Commercial mortgage-backed securities 34 56 (3) 7 13 (4) Other securities 921 2,535 (165) 269 670 (85) Total fixed maturity securities 9,606 $ 20,511 $ (2,056) 2,444 $ 4,128 $ (821) December 31, 2021 Fixed maturity securities: United States Government securities 51 $ 990 $ (11) 27 $ 176 $ (7) Government sponsored securities — — — 1 1 (1) Foreign government securities 188 143 (8) 68 41 (5) States, municipalities and political subdivisions 281 634 (9) 8 16 (1) Corporate securities 1,846 3,310 (57) 403 485 (21) Residential mortgage-backed securities 692 1,967 (26) 125 173 (9) Commercial mortgage-backed securities 2 4 (1) 4 8 (2) Other securities 511 1,707 (19) 50 85 (5) Total fixed maturity securities 3,571 $ 8,755 $ (131) 686 $ 985 $ (51) Although not material to our consolidated results of operations, during the nine months ended September 30, 2022, we recorded a combination of credit losses, losses on sales of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. At September 30, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material. Unrealized losses on our securities shown in the table above have not been recognized into income because, as of September 30, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the high rate of inflation and other market conditions and not by unfavorable changes in the credit quality characteristics that impact our assessment on collectability of principal and interest. We have evaluated qualitative and quantitative factors for indications of credit losses on our securities, including factors such as credit rating, foreign political conflicts, uncertainties around future ability to collect payment, significant declines in fair value and industry conditions, market data, and notifications of maturity and coupon default, and have recorded an allowance for credit losses in the amount of $10 and $6 at September 30, 2022 and December 31, 2021, respectively. The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations. Amortized Estimated Due in one year or less $ 911 $ 901 Due after one year through five years 7,364 6,871 Due after five years through ten years 9,535 8,467 Due after ten years 6,342 5,592 Mortgage-backed securities 4,825 4,317 Total fixed maturity securities $ 28,977 $ 26,148 During the three and nine months ended September 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,281 and $15,953, respectively. During the three and nine months ended September 30, 2021, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,620 and $8,570, respectively. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. Equity Securities A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows: September 30, 2022 December 31, 2021 Equity securities: Exchange traded funds $ 1,403 $ 1,750 Common equity securities 5 42 Private equity securities 95 89 Total $ 1,503 $ 1,881 Other Invested Assets Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive financial information from the companies. Investment Gains and Losses Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net (losses) gains: Fixed maturity securities: Gross realized gains from sales $ 8 $ 30 $ 44 $ 133 Gross realized losses from sales (99) (8) (353) (32) Impairment (losses) recoveries recognized in income (5) — (25) 1 Net realized (losses) gains from sales of fixed maturity securities (96) 22 (334) 102 Equity securities: Unrealized (losses) gains recognized on equity securities still held at the end of the period (43) (4) (192) 4 Net realized gains (losses) recognized on equity securities sold during the period 4 (1) (20) (57) Net losses on equity securities (39) (5) (212) (53) Other investments: Gross gains 95 2 126 9 Gross losses (2) (93) (45) (5) Impairment (losses) recoveries recognized in income (12) 1 (17) (5) Net losses (gains) on other investments 81 (90) 64 (1) Net (losses) gains on investments $ (54) $ (73) $ (482) $ 48 Accrued Investment Income At September 30, 2022 and December 31, 2021, accrued investment income totaled $228 and $205, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets. Securities Lending Programs We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,841 and $2,155 at September 30, 2022 and December 31, 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of September 30, 2022 and December 31, 2021. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. At September 30, 2022 and December 31, 2021, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,636 and $1,874, respectively, of United States Government securities for $180 and $281, respectively, and of Other securities for $25 and $0, respectively.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
Derivative Financial Instruments	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions. We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets. The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $231 and $239 at September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022 , we recognized net (losses) gains on non-hedging derivatives of $(3) and $43, respectively. During the three and nine months ended September 30, 2021 , we recognized net gains on non-hedging derivatives of $12 and $59, respectively. For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of this Form 10-Q.

Fair Value

Fair Value	9 Months Ended
Fair Value	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	Fair Value Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows: Level Input Input Definition Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets: Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I. Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets. Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets. Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures. Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty. A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows: Level I Level II Level III Total September 30, 2022 Assets: Cash equivalents $ 5,794 $ — $ — $ 5,794 Fixed maturity securities, available-for-sale: United States Government securities — 1,548 — 1,548 Government sponsored securities — 61 — 61 Foreign government securities — 251 — 251 States, municipalities and political subdivisions, tax-exempt — 4,081 — 4,081 Corporate securities — 12,079 129 12,208 Residential mortgage-backed securities — 4,247 — 4,247 Commercial mortgage-backed securities — 70 — 70 Other securities — 3,371 311 3,682 Total fixed maturity securities, available-for-sale — 25,708 440 26,148 Equity securities: Exchange traded funds 1,403 — — 1,403 Common equity securities 6 (1) — 5 Private equity securities — — 95 95 Total equity securities 1,409 (1) 95 1,503 Other invested assets - common equity securities 149 — — 149 Securities lending collateral — 2,841 — 2,841 Derivatives - other assets — 25 — 25 Total assets $ 7,352 $ 28,573 $ 535 $ 36,460 Liabilities: Derivatives - other liabilities $ — $ (70) $ — $ (70) Total liabilities $ — $ (70) $ — $ (70) December 31, 2021 Assets: Cash equivalents $ 2,415 $ — $ — $ 2,415 Fixed maturity securities, available-for-sale: United States Government securities — 1,432 — 1,432 Government sponsored securities — 68 — 68 Foreign government securities — 347 — 347 States, municipalities and political subdivisions, tax-exempt — 5,621 — 5,621 Corporate securities — 12,027 336 12,363 Residential mortgage-backed securities — 4,092 5 4,097 Commercial mortgage-backed securities — 64 — 64 Other securities — 2,888 19 2,907 Total fixed maturity securities, available-for-sale — 26,539 360 26,899 Equity securities: Exchange traded funds 1,750 — — 1,750 Common equity securities 8 34 — 42 Private equity securities — — 89 89 Total equity securities 1,758 34 89 1,881 Other invested assets - common equity securities 138 — — 138 Securities lending collateral — 2,155 — 2,155 Derivatives - other assets — 19 — 19 Total assets $ 4,311 $ 28,747 $ 449 $ 33,507 Liabilities: Derivatives - other liabilities $ — $ (1) $ — $ (1) Total liabilities $ — $ (1) $ — $ (1) A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows: Corporate Residential Other Equity Total Three Months Ended September 30, 2022 Beginning balance at July 1, 2022 $ 155 $ — $ 218 $ 94 $ 467 Total losses: Recognized in net income — — — — — Recognized in accumulated other comprehensive loss 1 — 17 — 18 Purchases 15 — 77 3 95 Sales (26) — (1) (2) (29) Settlements (10) — — — (10) Transfers out of Level III (6) — — — (6) Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535 Change in unrealized losses included in net income related to assets still held at September 30, 2022 $ — $ — $ — $ — $ — Three Months Ended September 30, 2021 Beginning balance at July 1, 2021 $ 351 $ 2 $ 7 $ 77 $ 437 Total gains: Recognized in net income 1 — — 5 6 Recognized in accumulated other comprehensive loss (1) — — — (1) Purchases 34 — — 3 37 Sales — — — (1) (1) Settlements (47) — — — (47) Transfers out of Level III (4) (1) (5) — (10) Ending balance at September 30, 2021 $ 334 $ 1 $ 2 $ 84 $ 421 Change in unrealized gains included in net income related to assets still held at September 30, 2021 $ — $ — $ — $ 5 $ 5 A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows: Corporate Residential Other Equity Total Nine Months Ended September 30, 2022 Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449 Total losses: Recognized in net income — — — 1 1 Recognized in accumulated other comprehensive loss (1) — 17 — 16 Purchases 40 — 281 24 345 Sales (201) — (1) (19) (221) Settlements (42) — — — (42) Transfers into Level III 9 — — — 9 Transfers out of Level III (12) (5) (5) — (22) Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535 Change in unrealized gains included in net income related to assets still held at September 30, 2022 $ — $ — $ — $ 1 $ 1 Nine Months Ended September 30, 2021 Beginning balance at January 1, 2021 $ 325 $ 2 $ 5 $ 60 $ 392 Total gains: Recognized in net income 2 — — 17 19 Recognized in accumulated other comprehensive loss 4 — — — 4 Purchases 135 — — 11 146 Sales (12) — — (4) (16) Settlements (118) — (1) — (119) Transfers out of Level III (2) (1) (2) — (5) Ending balance at September 30, 2021 $ 334 $ 1 $ 2 $ 84 $ 421 Change in unrealized gains included in net income related to assets still held at September 30, 2021 $ — $ — $ — $ 17 $ 17 There were no individually material transfers into or out of Level III during the three and nine months ended September 30, 2022 or 2021. Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Integra in the second quarter of 2022 and the acquisitions of myNEXUS and MMM during the second quarter of 2021. The net assets acquired in our acquisitions of Integra, myNEXUS and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30, 2022 or 2021. Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and nine months ended September 30, 2022 or 2021. In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets. Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value. The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below. The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets: Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value. Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value. Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities. Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade. A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows: Carrying Estimated Fair Value Level I Level II Level III Total September 30, 2022 Assets: Other invested assets $ 5,367 $ — $ — $ 5,367 $ 5,367 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Commercial paper 675 — 675 — 675 Notes 22,747 — 20,163 — 20,163 Convertible debentures 86 — 554 — 554 December 31, 2021 Assets: Other invested assets $ 5,087 $ — $ — $ 5,087 $ 5,087 Liabilities: Debt: Short-term borrowings 275 — 275 — 275 Commercial paper 300 — 300 — 300 Notes 22,384 — 25,150 — 25,150 Convertible debentures 72 — 687 — 687

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the three months ended September 30, 2022 and 2021, we recognized income tax expense of $533 and $494, respectively, which represent effective income tax rates of 24.8% and 24.7%, respectively. During the nine months ended September 30, 2022 and 2021, we recognized income tax expense of $1,557 and $1,555, respectively, which represent effective income tax rates of 23.5% and 23.8%, respectively. The decrease in our effective tax rate from the nine months ended September 30, 2021 was primarily related to the tax impact of expected geographic changes in our mix of 2022 earnings. Income taxes receivable totaled $214 and $173 at September 30, 2022 and December 31, 2021, respectively. We recognized the income taxes receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.

Medical Claims Payable

Medical Claims Payable	9 Months Ended
Medical Claims Payable	Sep. 30, 2022
Liability for Claims and Claims Adjustment Expense [Abstract]
Medical Claims payable	Medical Claims Payable A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows: Commercial Government Other Total Gross medical claims payable, beginning of period $ 3,847 $ 9,157 $ 278 $ 13,282 Ceded medical claims payable, beginning of period (13) (8) — (21) Net medical claims payable, beginning of period 3,834 9,149 278 13,261 Business combinations and purchase adjustments 3 130 — 133 Net incurred medical claims: Current period 22,049 60,971 1,157 84,177 Prior periods redundancies (183) (639) (79) (901) Total net incurred medical claims 21,866 60,332 1,078 83,276 Net payments attributable to: Current period medical claims 18,604 50,950 899 70,453 Prior periods medical claims 3,181 7,854 184 11,219 Total net payments 21,785 58,804 1,083 81,672 Net medical claims payable, end of period 3,918 10,807 273 14,998 Ceded medical claims payable, end of period 3 — — 3 Gross medical claims payable, end of period $ 3,921 $ 10,807 $ 273 $ 15,001 At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively. At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively. At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively. A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows: Commercial Government Other Total Gross medical claims payable, beginning of period $ 3,294 $ 7,646 $ 195 $ 11,135 Ceded medical claims payable, beginning of period (13) (33) — (46) Net medical claims payable, beginning of period 3,281 7,613 195 11,089 Business combinations and purchase adjustments — 375 45 420 Net incurred medical claims: Current period 20,499 52,422 1,176 74,097 Prior periods redundancies (496) (1,309) (17) (1,822) Total net incurred medical claims 20,003 51,113 1,159 72,275 Net payments attributable to: Current period medical claims 16,985 44,160 978 62,123 Prior periods medical claims 2,450 5,781 169 8,400 Total net payments 19,435 49,941 1,147 70,523 Net medical claims payable, end of period 3,849 9,160 252 13,261 Ceded medical claims payable, end of period 15 23 — 38 Gross medical claims payable, end of period $ 3,864 $ 9,183 $ 252 $ 13,299 The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022. The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows: Three Months Ended Nine Months Ended September 30, 2022 March 31, 2022 June 30, 2022 September 30, 2022 Net incurred medical claims: Commercial & Specialty Business $ 6,834 $ 7,522 $ 7,510 $ 21,866 Government Business 19,943 19,788 20,601 60,332 Other 354 324 400 1,078 Total net incurred medical claims 27,131 27,634 28,511 83,276 Quality improvement and other claims expense 1,084 1,143 893 3,120 Benefit expense $ 28,215 $ 28,777 $ 29,404 $ 86,396 During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022. The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows: Three Months Ended Nine Months Ended September 30, 2021 March 31, 2021 June 30, 2021 September 30, 2021 Net incurred medical claims: Commercial & Specialty Business $ 6,072 $ 6,718 $ 7,213 $ 20,003 Government Business 16,319 16,723 18,071 51,113 Other 336 403 420 1,159 Total net incurred medical claims 22,727 23,844 25,704 72,275 Quality improvement and other claims expense 972 919 941 2,832 Benefit expense $ 23,699 $ 24,763 $ 26,645 $ 75,107 The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows: Commercial Government Other Total Net medical claims payable, end of period $ 3,918 $ 10,807 $ 273 $ 14,998 Ceded medical claims payable, end of period 3 — — 3 Insurance lines other than short duration — 241 — 241 Gross medical claims payable, end of period $ 3,921 $ 11,048 $ 273 $ 15,242

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt We generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2022 and December 31, 2021, we had $22,722 and $22,359, respectively, outstanding under these notes. On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes. On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 (the “2032 Notes”) and $700 aggregate principal amount of 4.550% Notes due 2052 (the “2052 Notes”) under our shelf registration statement. Interest on the 2032 Notes and 2052 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program. We have an unsecured surplus note with an outstanding principal balance of $25 at both September 30, 2022 and December 31, 2021. We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the nine months ended September 30, 2022 or the year ended December 31, 2021. Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. At September 30, 2022 and December 31, 2021, there were no amounts outstanding under our Subsidiary Credit Facilities. We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At September 30, 2022 and December 31, 2021, we had $675 and $300, respectively, outstanding under this program. We have outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), which are governed by an indenture (the “indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option. During the three and nine months ended September 30, 2022, $4 and $19 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three and nine months ended September 30, 2022 of $25 and $132, respectively. The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures: Outstanding principal amount $ 86 Net debt carrying amount $ 86 Conversion rate (shares of common stock per $1,000 of principal amount) 14.2967 Effective conversion price (per $1,000 of principal amount) $ 69.9462 We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $265 and $275 of outstanding short-term borrowings from the FHLBs at September 30, 2022 and December 31, 2021, respectively. All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
Commitments And Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies Litigation and Regulatory Proceedings In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses. Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at September 30, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made. Blue Cross Blue Shield Antitrust Litigation We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard ® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard ® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed. The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. In excess of eight thousand claims were submitted by the November 2021 claims submission deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement and requested supplemental briefing that was submitted. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members, which notice process was completed in March 2022. The deadline for objections to the supplemental notice along with opt-outs was in May 2022 . In August 2022, the Court issued a final approval order for the Subscriber Settlement Agreement. The Court amended its final approval order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the final approval order, which the Court denied. In compliance with the Subscriber Settlement Agreement, the Company paid its remaining $506 portion of the settlement fund into an escrow account in September 2022, for an aggregate settlement payment by the Company of $596. Four notices of appeal of the final approval order were filed by the September 2022 deadline. Those appeals will proceed in the United States Court of Appeals for the Eleventh Circuit. In October 2022, the subscriber plaintiffs filed a motion to consolidate and expedite the four appeals. After all appellate rights have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective. In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to providers’ claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued (i) an order granting certain defendants’ motion for partial summary judgment against provider plaintiffs who had previously released claims against such defendants, and (ii) an order granting provider plaintiffs’ motion for partial summary judgment, holding that Ohio v. American Express Co . does not affect the standard of review in this case. In August 2022, the Court issued (i) an order granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) an order denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined. A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.); JetBlue Airways Corp., et al. v. Anthem, Inc., et al. , No. 2:22-cv-00558-GMB (N.D. Ala.); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al. , No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc. , No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al. , No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al. , No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined. Blue Cross of California Taxation Litigation In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint. Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation. In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In November 2021, the plaintiff appealed the order granting BCC's motion for summary judgment. BCC’s responding brief was filed in March 2022. Plaintiff’s reply was filed in May 2022. We estimate that the appeal will be heard in the winter of 2022. We intend to vigorously defend the appeal of this lawsuit. Express Scripts, Inc. Pharmacy Benefit Management Litigation In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc. , in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such action, the only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined. Medicare Risk Adjustment Litigation In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc . The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in such court. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined. Investigations of CareMore and HealthSun With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarter of 2021, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing. Other Contingencies From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. Contractual Obligations and Commitments In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at September 30, 2022 is approximately $830. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.

Capital Stock

Capital Stock	9 Months Ended
Capital Stock	Sep. 30, 2022
Banking Regulation, Total Capital [Abstract]
Capital Stock	Capital Stock Use of Capital – Dividends and Stock Repurchase Program We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows: Declaration Date Record Date Payment Date Cash Dividend per Share Total Nine Months Ended September 30, 2022 January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309 April 19, 2022 June 10, 2022 June 24, 2022 $1.28 $ 309 July 19, 2022 September 9, 2022 September 23, 2022 $1.28 $ 306 Nine Months Ended September 30, 2021 January 26, 2021 March 10, 2021 March 25, 2021 $1.13 $ 277 April 20, 2021 June 10, 2021 June 25, 2021 $1.13 $ 278 July 20, 2021 September 10, 2021 September 24, 2021 $1.13 $ 276 On October 18, 2022, our Audit Committee declared a fourth quarter 2022 dividend to shareholders of $1.28 per share, payable on December 21, 2022 to shareholders of record at the close of business on December 5, 2022. Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows: Nine Months Ended September 30 2022 2021 Shares repurchased 3.7 3.9 Average price per share $ 473.36 $ 356.43 Aggregate cost $ 1,748 $ 1,378 Authorization remaining at the end of the period $ 2,444 $ 4,714 For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K. Stock Incentive Plan s A summary of stock option activity for the nine months ended September 30, 2022 is as follows: Number of Weighted- Weighted- Aggregate Outstanding at January 1, 2022 2.9 $ 255.50 Granted 0.5 452.34 Exercised (0.4) 243.39 Forfeited or expired (0.1) 339.52 Outstanding at September 30, 2022 2.9 291.95 6.56 $ 477 Exercisable at September 30, 2022 1.7 239.27 5.35 $ 370 A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows: Restricted Weighted- Nonvested at January 1, 2022 1.3 $ 299.65 Granted 0.6 453.16 Vested (0.6) 301.44 Forfeited (0.1) 345.25 Nonvested at September 30, 2022 1.2 356.33 During the nine months ended September 30, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024 based on results in the three year period. Fair Value We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K. The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30 2022 2021 Risk-free interest rate 1.97 % 1.44 % Volatility factor 29.00 % 30.00 % Quarterly dividend yield 0.282 % 0.360 % Weighted-average expected life (years) 5.10 5.50 The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30 2022 2021 Options granted during the period $ 116.85 $ 79.51 Restricted stock awards granted during the period 453.16 315.54

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
Accumulated Other Comprehensive Loss	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net unrealized investment (losses) gains: Beginning of period balance $ (1,489) $ 762 $ 494 $ 949 Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively (719) (80) (2,914) (203) Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively 80 (17) 284 (81) Other comprehensive loss (639) (97) (2,630) (284) Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively 3 1 11 1 End of period balance (2,125) 666 (2,125) 666 Non-credit components of impairments on investments: Beginning of period balance (2) — — (2) Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively (1) (1) (3) 1 End of period balance (3) (1) (3) (1) Net cash flow hedges: Beginning of period balance (233) (244) (239) (250) Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively 2 4 8 10 End of period balance (231) (240) (231) (240) Pension and other postretirement benefits: Beginning of period balance (413) (534) (429) (552) Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively 7 8 23 26 End of period balance (406) (526) (406) (526) Foreign currency translation adjustments: Beginning of period balance (12) (1) (4) 5 Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively (7) (1) (15) (7) End of period balance (19) (2) (19) (2) Total: Total beginning of period accumulated other comprehensive (loss) (2,149) (17) (178) 150 Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively (638) (87) (2,617) (254) Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively 3 1 11 1 Total end of period accumulated other comprehensive loss $ (2,784) $ (103) $ (2,784) $ (103)

Earnings Per Share

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings per Share The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Denominator for basic earnings per share – weighted-average shares 239.6 243.4 240.5 244.3 Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 2.6 2.6 2.8 2.9 Denominator for diluted earnings per share 242.2 246.0 243.3 247.2 During the three months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.5 and 0.0, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the nine months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.4 and 0.3, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive. During the three and nine months ended September 30, 2022, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2022 through 2024. During the three and nine months ended September 30, 2021, we issued approximately 0.1 and 1.0 restricted stock units under our stock incentive plans, 0.0 and 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2021 through 2023. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information As discussed in Note 1 “Organization”, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future. Currently, there are no changes to our segments associated with this branding strategy. The results of our operations continue to be described through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. Our Commercial & Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard ® members. The Commercial & Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits. Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, and services provided to the federal government in connection with the FEHB program. Our IngenioRx segment includes our PBM business. IngenioRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. Our Other segment includes our Diversified Business Group, now known as Carelon, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments. We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. Affiliated revenues represent revenues or cost for services provided to our subsidiaries by IngenioRx and Carelon, formerly known as our Diversified Business Group, as well as certain back-office services provided by our international businesses, and are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation. Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows: Commercial Government IngenioRx Other Eliminations Total Three Months Ended September 30, 2022 Operating revenue - unaffiliated $ 10,494 $ 24,571 $ 3,971 $ 589 $ — $ 39,625 Operating revenue - affiliated — — 3,278 2,776 (6,054) — Operating gain 785 868 516 101 — 2,270 Three Months Ended September 30, 2021 Operating revenue - unaffiliated $ 9,863 $ 21,658 $ 3,369 $ 658 $ — $ 35,548 Operating revenue - affiliated — — 3,180 2,012 (5,192) — Operating gain 620 967 445 27 — 2,059 Nine Months Ended September 30, 2022 Operating revenue - unaffiliated $ 31,324 $ 72,164 $ 10,838 $ 1,667 $ — $ 115,993 Operating revenue - affiliated — — 10,165 8,217 (18,382) — Operating gain 2,673 2,653 1,393 365 — 7,084 Nine Months Ended September 30, 2021 Operating revenue - unaffiliated $ 28,904 $ 61,007 $ 9,131 $ 1,883 $ — $ 100,925 Operating revenue - affiliated — — 9,499 5,674 (15,173) — Operating gain 2,679 2,313 1,257 52 — 6,301 The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Commercial & Specialty Business Managed care products $ 8,478 $ 8,005 $ 25,500 $ 23,481 Managed care services 1,610 1,489 4,618 4,291 Dental/Vision products and services 360 342 1,075 1,013 Other 46 27 131 119 Total Commercial & Specialty Business 10,494 9,863 31,324 28,904 Government Business Managed care products 24,456 21,565 71,823 60,711 Managed care services 115 93 341 296 Total Government Business 24,571 21,658 72,164 61,007 IngenioRx Pharmacy products and services 7,249 6,549 21,003 18,630 Other Integrated health services 3,153 2,506 9,083 7,121 Other 212 164 801 436 Total Other 3,365 2,670 9,884 7,557 Eliminations Eliminations (6,054) (5,192) (18,382) (15,173) Total product revenues $ 39,625 $ 35,548 $ 115,993 $ 100,925 The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk. A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Reportable segments’ operating revenue $ 39,625 $ 35,548 $ 115,993 $ 100,925 Net investment income 371 335 1,112 1,026 Net (losses) gains on financial instruments (57) (61) (439) 107 Total revenues $ 39,939 $ 35,822 $ 116,666 $ 102,058 A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Income before income tax expense $ 2,146 $ 1,996 $ 6,615 $ 6,525 Net investment income (371) (335) (1,112) (1,026) Net losses (gains) on financial instruments 57 61 439 (107) Interest expense 213 201 622 598 Amortization of other intangible assets 225 136 520 306 Loss on extinguishment of debt — — — 5 Reportable segments’ operating gain $ 2,270 $ 2,059 $ 7,084 $ 6,301

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	Leases We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 12 years. The information related to our leases is as follows: Balance Sheet Location September 30, 2022 December 31, 2021 Operating Leases Right-of-use assets Other noncurrent assets $ 600 $ 628 Lease liabilities, current Other current liabilities 182 133 Lease liabilities, noncurrent Other noncurrent liabilities 739 864 Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Expense Operating lease expense $ 35 $ 37 $ 100 $ 100 Short-term lease expense 11 10 35 34 Sublease income (1) (1) (3) (3) Total lease expense $ 45 $ 46 $ 132 $ 131 Other information Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 53 $ 53 $ 158 $ 141 Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 23 $ 32 $ 62 $ 192 As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 2.79% at September 30, 2022 and 2.69% at December 31, 2021. Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows: 2022 (excluding the nine months ended September 30, 2022) $ 54 2023 207 2024 179 2025 142 2026 105 Thereafter 345 Total future minimum payments 1,032 Less imputed interest (111) Total lease liabilities $ 921 As of September 30, 2022, we have no new leases which will commence during the fourth quarter of 2022.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
Goodwill and Other Intangible Assets	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Goodwill and Other Intangible Assets A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows: Commercial Government IngenioRx Other Total Balance as of January 1, 2021 $ 11,593 $ 8,331 $ 48 $ 1,719 $ 21,691 Acquisitions and adjustments — 2,018 11 508 2,537 Balance as of December 31, 2021 11,593 10,349 59 2,227 24,228 Acquisitions and adjustments 18 126 — 9 153 Balance as of September 30, 2022 $ 11,611 $ 10,475 $ 59 $ 2,236 $ 24,381 Accumulated impairment as of September 30, 2022 $ — $ — $ — $ — $ — The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Gross Accumulated Net Gross Accumulated Net Intangible assets with finite lives: Customer relationships $ 5,791 $ (3,580) $ 2,211 $ 5,598 $ (3,236) $ 2,362 Provider and hospital relationships 326 (142) 184 324 (129) 195 Other 920 (310) 610 610 (141) 469 Total 7,037 (4,032) 3,005 6,532 (3,506) 3,026 Intangible assets with indefinite lives: Blue Cross and Blue Shield and other trademarks 5,991 — 5,991 6,299 — 6,299 State Medicaid licenses 1,540 — 1,540 1,290 — 1,290 Total 7,531 — 7,531 7,589 — 7,589 Other intangible assets $ 14,568 $ (4,032) $ 10,536 $ 14,121 $ (3,506) $ 10,615 During the nine months ended September 30, 2022, we recorded intangible assets related to Integra and also reclassified $308 of trademarks with indefinite lives to intangible assets with finite lives - Other, which relates to our new branding strategy. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place. Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized. As of September 30, 2022, the estimated amortization expense for the year ending December 31, 2022 and each of the five succeeding years is as follows: 2022, $748; 2023, $735; 2024, $370; 2025, $311; 2026, $258; and 2027, $219.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Foreign Currency	Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents	Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investment, Policy	Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default. For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income. The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets. We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets. Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold. We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivable	Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts. Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively. Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively. Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.
Revenue Recognition	Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
New Accounting Pronouncements	Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) . The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows. Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments

Business Optimization Initiat_2

Business Optimization Initiatives (Tables)	9 Months Ended
Business Optimization Initiatives (Tables)	Sep. 30, 2022
Business Optimization Initiatives [Abstract]
Business Optimization Initiatives	Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020. Commercial & Specialty Business Government Business IngenioRx Other Total 2020 Business Optimization Initiatives Employee termination costs: Liability for employee termination costs at January 1, 2022 $ 61 $ 57 $ 1 $ 3 $ 122 Payments (16) (14) — — (30) Liability for employee termination costs at September 30, 2022 $ 45 $ 43 $ 1 $ 3 $ 92

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Sep. 30, 2022
Investments [Abstract]
Current and Long-Term Investments, Available-For-Sale	A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows: Cost or Amortized Cost Gross Gross Allowance Estimated September 30, 2022 Fixed maturity securities: United States Government securities $ 1,673 $ — $ (125) $ — $ 1,548 Government sponsored securities 65 — (4) — 61 Foreign government securities 322 — (70) (1) 251 States, municipalities and political subdivisions 4,431 5 (355) — 4,081 Corporate securities 13,766 9 (1,560) (7) 12,208 Residential mortgage-backed securities 4,748 7 (506) (2) 4,247 Commercial mortgage-backed securities 77 — (7) — 70 Other securities 3,895 37 (250) — 3,682 Total fixed maturity securities $ 28,977 $ 58 $ (2,877) $ (10) $ 26,148 December 31, 2021 Fixed maturity securities: United States Government securities $ 1,443 $ 7 $ (18) $ — $ 1,432 Government sponsored securities 65 4 (1) — 68 Foreign government securities 353 7 (13) — 347 States, municipalities and political subdivisions 5,321 310 (10) — 5,621 Corporate securities 12,044 401 (78) (4) 12,363 Residential mortgage-backed securities 4,059 75 (35) (2) 4,097 Commercial mortgage-backed securities 65 2 (3) — 64 Other securities 2,907 24 (24) — 2,907 Total fixed maturity securities $ 26,257 $ 830 $ (182) $ (6) $ 26,899
Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position	For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: Less than 12 Months 12 Months or Greater (Securities are whole amounts) Number of Estimated Gross Number of Estimated Gross September 30, 2022 Fixed maturity securities: United States Government securities 65 $ 911 $ (77) 29 $ 303 $ (48) Government sponsored securities 40 61 (4) 1 — — Foreign government securities 225 169 (34) 151 81 (36) States, municipalities and political subdivisions 1,964 3,602 (314) 139 200 (41) Corporate securities 4,322 10,228 (1,165) 1,318 1,679 (395) Residential mortgage-backed securities 2,035 2,949 (294) 530 1,182 (212) Commercial mortgage-backed securities 34 56 (3) 7 13 (4) Other securities 921 2,535 (165) 269 670 (85) Total fixed maturity securities 9,606 $ 20,511 $ (2,056) 2,444 $ 4,128 $ (821) December 31, 2021 Fixed maturity securities: United States Government securities 51 $ 990 $ (11) 27 $ 176 $ (7) Government sponsored securities — — — 1 1 (1) Foreign government securities 188 143 (8) 68 41 (5) States, municipalities and political subdivisions 281 634 (9) 8 16 (1) Corporate securities 1,846 3,310 (57) 403 485 (21) Residential mortgage-backed securities 692 1,967 (26) 125 173 (9) Commercial mortgage-backed securities 2 4 (1) 4 8 (2) Other securities 511 1,707 (19) 50 85 (5) Total fixed maturity securities 3,571 $ 8,755 $ (131) 686 $ 985 $ (51)
Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity	The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations. Amortized Estimated Due in one year or less $ 911 $ 901 Due after one year through five years 7,364 6,871 Due after five years through ten years 9,535 8,467 Due after ten years 6,342 5,592 Mortgage-backed securities 4,825 4,317 Total fixed maturity securities $ 28,977 $ 26,148
Investments In Equity Securities	A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows: September 30, 2022 December 31, 2021 Equity securities: Exchange traded funds $ 1,403 $ 1,750 Common equity securities 5 42 Private equity securities 95 89 Total $ 1,503 $ 1,881
Net Investment Gains (Losses)	Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net (losses) gains: Fixed maturity securities: Gross realized gains from sales $ 8 $ 30 $ 44 $ 133 Gross realized losses from sales (99) (8) (353) (32) Impairment (losses) recoveries recognized in income (5) — (25) 1 Net realized (losses) gains from sales of fixed maturity securities (96) 22 (334) 102 Equity securities: Unrealized (losses) gains recognized on equity securities still held at the end of the period (43) (4) (192) 4 Net realized gains (losses) recognized on equity securities sold during the period 4 (1) (20) (57) Net losses on equity securities (39) (5) (212) (53) Other investments: Gross gains 95 2 126 9 Gross losses (2) (93) (45) (5) Impairment (losses) recoveries recognized in income (12) 1 (17) (5) Net losses (gains) on other investments 81 (90) 64 (1) Net (losses) gains on investments $ (54) $ (73) $ (482) $ 48

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
Fair Value (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis	A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows: Level I Level II Level III Total September 30, 2022 Assets: Cash equivalents $ 5,794 $ — $ — $ 5,794 Fixed maturity securities, available-for-sale: United States Government securities — 1,548 — 1,548 Government sponsored securities — 61 — 61 Foreign government securities — 251 — 251 States, municipalities and political subdivisions, tax-exempt — 4,081 — 4,081 Corporate securities — 12,079 129 12,208 Residential mortgage-backed securities — 4,247 — 4,247 Commercial mortgage-backed securities — 70 — 70 Other securities — 3,371 311 3,682 Total fixed maturity securities, available-for-sale — 25,708 440 26,148 Equity securities: Exchange traded funds 1,403 — — 1,403 Common equity securities 6 (1) — 5 Private equity securities — — 95 95 Total equity securities 1,409 (1) 95 1,503 Other invested assets - common equity securities 149 — — 149 Securities lending collateral — 2,841 — 2,841 Derivatives - other assets — 25 — 25 Total assets $ 7,352 $ 28,573 $ 535 $ 36,460 Liabilities: Derivatives - other liabilities $ — $ (70) $ — $ (70) Total liabilities $ — $ (70) $ — $ (70) December 31, 2021 Assets: Cash equivalents $ 2,415 $ — $ — $ 2,415 Fixed maturity securities, available-for-sale: United States Government securities — 1,432 — 1,432 Government sponsored securities — 68 — 68 Foreign government securities — 347 — 347 States, municipalities and political subdivisions, tax-exempt — 5,621 — 5,621 Corporate securities — 12,027 336 12,363 Residential mortgage-backed securities — 4,092 5 4,097 Commercial mortgage-backed securities — 64 — 64 Other securities — 2,888 19 2,907 Total fixed maturity securities, available-for-sale — 26,539 360 26,899 Equity securities: Exchange traded funds 1,750 — — 1,750 Common equity securities 8 34 — 42 Private equity securities — — 89 89 Total equity securities 1,758 34 89 1,881 Other invested assets - common equity securities 138 — — 138 Securities lending collateral — 2,155 — 2,155 Derivatives - other assets — 19 — 19 Total assets $ 4,311 $ 28,747 $ 449 $ 33,507 Liabilities: Derivatives - other liabilities $ — $ (1) $ — $ (1) Total liabilities $ — $ (1) $ — $ (1)
Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs	A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows: Corporate Residential Other Equity Total Three Months Ended September 30, 2022 Beginning balance at July 1, 2022 $ 155 $ — $ 218 $ 94 $ 467 Total losses: Recognized in net income — — — — — Recognized in accumulated other comprehensive loss 1 — 17 — 18 Purchases 15 — 77 3 95 Sales (26) — (1) (2) (29) Settlements (10) — — — (10) Transfers out of Level III (6) — — — (6) Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535 Change in unrealized losses included in net income related to assets still held at September 30, 2022 $ — $ — $ — $ — $ — Three Months Ended September 30, 2021 Beginning balance at July 1, 2021 $ 351 $ 2 $ 7 $ 77 $ 437 Total gains: Recognized in net income 1 — — 5 6 Recognized in accumulated other comprehensive loss (1) — — — (1) Purchases 34 — — 3 37 Sales — — — (1) (1) Settlements (47) — — — (47) Transfers out of Level III (4) (1) (5) — (10) Ending balance at September 30, 2021 $ 334 $ 1 $ 2 $ 84 $ 421 Change in unrealized gains included in net income related to assets still held at September 30, 2021 $ — $ — $ — $ 5 $ 5 A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows: Corporate Residential Other Equity Total Nine Months Ended September 30, 2022 Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449 Total losses: Recognized in net income — — — 1 1 Recognized in accumulated other comprehensive loss (1) — 17 — 16 Purchases 40 — 281 24 345 Sales (201) — (1) (19) (221) Settlements (42) — — — (42) Transfers into Level III 9 — — — 9 Transfers out of Level III (12) (5) (5) — (22) Ending balance at September 30, 2022 $ 129 $ — $ 311 $ 95 $ 535 Change in unrealized gains included in net income related to assets still held at September 30, 2022 $ — $ — $ — $ 1 $ 1 Nine Months Ended September 30, 2021 Beginning balance at January 1, 2021 $ 325 $ 2 $ 5 $ 60 $ 392 Total gains: Recognized in net income 2 — — 17 19 Recognized in accumulated other comprehensive loss 4 — — — 4 Purchases 135 — — 11 146 Sales (12) — — (4) (16) Settlements (118) — (1) — (119) Transfers out of Level III (2) (1) (2) — (5) Ending balance at September 30, 2021 $ 334 $ 1 $ 2 $ 84 $ 421 Change in unrealized gains included in net income related to assets still held at September 30, 2021 $ — $ — $ — $ 17 $ 17
Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet	A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows: Carrying Estimated Fair Value Level I Level II Level III Total September 30, 2022 Assets: Other invested assets $ 5,367 $ — $ — $ 5,367 $ 5,367 Liabilities: Debt: Short-term borrowings 265 — 265 — 265 Commercial paper 675 — 675 — 675 Notes 22,747 — 20,163 — 20,163 Convertible debentures 86 — 554 — 554 December 31, 2021 Assets: Other invested assets $ 5,087 $ — $ — $ 5,087 $ 5,087 Liabilities: Debt: Short-term borrowings 275 — 275 — 275 Commercial paper 300 — 300 — 300 Notes 22,384 — 25,150 — 25,150 Convertible debentures 72 — 687 — 687

Medical Claims Payable (Tables)

Medical Claims Payable (Tables)	9 Months Ended
Medical Claims Payable (Tables)	Sep. 30, 2022
Liability for Claims and Claims Adjustment Expense [Abstract]
Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable	A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows: Commercial Government Other Total Gross medical claims payable, beginning of period $ 3,847 $ 9,157 $ 278 $ 13,282 Ceded medical claims payable, beginning of period (13) (8) — (21) Net medical claims payable, beginning of period 3,834 9,149 278 13,261 Business combinations and purchase adjustments 3 130 — 133 Net incurred medical claims: Current period 22,049 60,971 1,157 84,177 Prior periods redundancies (183) (639) (79) (901) Total net incurred medical claims 21,866 60,332 1,078 83,276 Net payments attributable to: Current period medical claims 18,604 50,950 899 70,453 Prior periods medical claims 3,181 7,854 184 11,219 Total net payments 21,785 58,804 1,083 81,672 Net medical claims payable, end of period 3,918 10,807 273 14,998 Ceded medical claims payable, end of period 3 — — 3 Gross medical claims payable, end of period $ 3,921 $ 10,807 $ 273 $ 15,001 At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively. At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively. At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively. A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows: Commercial Government Other Total Gross medical claims payable, beginning of period $ 3,294 $ 7,646 $ 195 $ 11,135 Ceded medical claims payable, beginning of period (13) (33) — (46) Net medical claims payable, beginning of period 3,281 7,613 195 11,089 Business combinations and purchase adjustments — 375 45 420 Net incurred medical claims: Current period 20,499 52,422 1,176 74,097 Prior periods redundancies (496) (1,309) (17) (1,822) Total net incurred medical claims 20,003 51,113 1,159 72,275 Net payments attributable to: Current period medical claims 16,985 44,160 978 62,123 Prior periods medical claims 2,450 5,781 169 8,400 Total net payments 19,435 49,941 1,147 70,523 Net medical claims payable, end of period 3,849 9,160 252 13,261 Ceded medical claims payable, end of period 15 23 — 38 Gross medical claims payable, end of period $ 3,864 $ 9,183 $ 252 $ 13,299 The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.
Reconciliation of Net Incurred Medical Claims to Benefit Expense	The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows: Three Months Ended Nine Months Ended September 30, 2022 March 31, 2022 June 30, 2022 September 30, 2022 Net incurred medical claims: Commercial & Specialty Business $ 6,834 $ 7,522 $ 7,510 $ 21,866 Government Business 19,943 19,788 20,601 60,332 Other 354 324 400 1,078 Total net incurred medical claims 27,131 27,634 28,511 83,276 Quality improvement and other claims expense 1,084 1,143 893 3,120 Benefit expense $ 28,215 $ 28,777 $ 29,404 $ 86,396 During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022. The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows: Three Months Ended Nine Months Ended September 30, 2021 March 31, 2021 June 30, 2021 September 30, 2021 Net incurred medical claims: Commercial & Specialty Business $ 6,072 $ 6,718 $ 7,213 $ 20,003 Government Business 16,319 16,723 18,071 51,113 Other 336 403 420 1,159 Total net incurred medical claims 22,727 23,844 25,704 72,275 Quality improvement and other claims expense 972 919 941 2,832 Benefit expense $ 23,699 $ 24,763 $ 26,645 $ 75,107
Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable	The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows: Commercial Government Other Total Net medical claims payable, end of period $ 3,918 $ 10,807 $ 273 $ 14,998 Ceded medical claims payable, end of period 3 — — 3 Insurance lines other than short duration — 241 — 241 Gross medical claims payable, end of period $ 3,921 $ 11,048 $ 273 $ 15,242

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Debenture Terms	The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures: Outstanding principal amount $ 86 Net debt carrying amount $ 86 Conversion rate (shares of common stock per $1,000 of principal amount) 14.2967 Effective conversion price (per $1,000 of principal amount) $ 69.9462

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
Capital Stock (Tables)	Sep. 30, 2022
Banking Regulation, Total Capital [Abstract]
Summary of Cash Dividend Activity	A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows: Declaration Date Record Date Payment Date Cash Dividend per Share Total Nine Months Ended September 30, 2022 January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309 April 19, 2022 June 10, 2022 June 24, 2022 $1.28 $ 309 July 19, 2022 September 9, 2022 September 23, 2022 $1.28 $ 306 Nine Months Ended September 30, 2021 January 26, 2021 March 10, 2021 March 25, 2021 $1.13 $ 277 April 20, 2021 June 10, 2021 June 25, 2021 $1.13 $ 278 July 20, 2021 September 10, 2021 September 24, 2021 $1.13 $ 276
Summary of Share Repurchases	A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows: Nine Months Ended September 30 2022 2021 Shares repurchased 3.7 3.9 Average price per share $ 473.36 $ 356.43 Aggregate cost $ 1,748 $ 1,378 Authorization remaining at the end of the period $ 2,444 $ 4,714
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended September 30, 2022 is as follows: Number of Weighted- Weighted- Aggregate Outstanding at January 1, 2022 2.9 $ 255.50 Granted 0.5 452.34 Exercised (0.4) 243.39 Forfeited or expired (0.1) 339.52 Outstanding at September 30, 2022 2.9 291.95 6.56 $ 477 Exercisable at September 30, 2022 1.7 239.27 5.35 $ 370
Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units	A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows: Restricted Weighted- Nonvested at January 1, 2022 1.3 $ 299.65 Granted 0.6 453.16 Vested (0.6) 301.44 Forfeited (0.1) 345.25 Nonvested at September 30, 2022 1.2 356.33
Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods	The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30 2022 2021 Risk-free interest rate 1.97 % 1.44 % Volatility factor 29.00 % 30.00 % Quarterly dividend yield 0.282 % 0.360 % Weighted-average expected life (years) 5.10 5.50
Schedule of Weighted-Average Fair Values Determined for the Periods	The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30 2022 2021 Options granted during the period $ 116.85 $ 79.51 Restricted stock awards granted during the period 453.16 315.54

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
Accumulated Other Comprehensive Loss (Tables)	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Reconciliation Of Components Of Accumulated Other Comprehensive Loss	A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net unrealized investment (losses) gains: Beginning of period balance $ (1,489) $ 762 $ 494 $ 949 Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively (719) (80) (2,914) (203) Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively 80 (17) 284 (81) Other comprehensive loss (639) (97) (2,630) (284) Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively 3 1 11 1 End of period balance (2,125) 666 (2,125) 666 Non-credit components of impairments on investments: Beginning of period balance (2) — — (2) Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively (1) (1) (3) 1 End of period balance (3) (1) (3) (1) Net cash flow hedges: Beginning of period balance (233) (244) (239) (250) Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively 2 4 8 10 End of period balance (231) (240) (231) (240) Pension and other postretirement benefits: Beginning of period balance (413) (534) (429) (552) Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively 7 8 23 26 End of period balance (406) (526) (406) (526) Foreign currency translation adjustments: Beginning of period balance (12) (1) (4) 5 Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively (7) (1) (15) (7) End of period balance (19) (2) (19) (2) Total: Total beginning of period accumulated other comprehensive (loss) (2,149) (17) (178) 150 Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively (638) (87) (2,617) (254) Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively 3 1 11 1 Total end of period accumulated other comprehensive loss $ (2,784) $ (103) $ (2,784) $ (103)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Denominator for Basic and Diluted Earnings Per Share	The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Denominator for basic earnings per share – weighted-average shares 239.6 243.4 240.5 244.3 Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 2.6 2.6 2.8 2.9 Denominator for diluted earnings per share 242.2 246.0 243.3 247.2

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2022
Segment Reporting [Abstract]
Financial Data By Reportable Segment	Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows: Commercial Government IngenioRx Other Eliminations Total Three Months Ended September 30, 2022 Operating revenue - unaffiliated $ 10,494 $ 24,571 $ 3,971 $ 589 $ — $ 39,625 Operating revenue - affiliated — — 3,278 2,776 (6,054) — Operating gain 785 868 516 101 — 2,270 Three Months Ended September 30, 2021 Operating revenue - unaffiliated $ 9,863 $ 21,658 $ 3,369 $ 658 $ — $ 35,548 Operating revenue - affiliated — — 3,180 2,012 (5,192) — Operating gain 620 967 445 27 — 2,059 Nine Months Ended September 30, 2022 Operating revenue - unaffiliated $ 31,324 $ 72,164 $ 10,838 $ 1,667 $ — $ 115,993 Operating revenue - affiliated — — 10,165 8,217 (18,382) — Operating gain 2,673 2,653 1,393 365 — 7,084 Nine Months Ended September 30, 2021 Operating revenue - unaffiliated $ 28,904 $ 61,007 $ 9,131 $ 1,883 $ — $ 100,925 Operating revenue - affiliated — — 9,499 5,674 (15,173) — Operating gain 2,679 2,313 1,257 52 — 6,301
Major Product Revenue by Segment	The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Commercial & Specialty Business Managed care products $ 8,478 $ 8,005 $ 25,500 $ 23,481 Managed care services 1,610 1,489 4,618 4,291 Dental/Vision products and services 360 342 1,075 1,013 Other 46 27 131 119 Total Commercial & Specialty Business 10,494 9,863 31,324 28,904 Government Business Managed care products 24,456 21,565 71,823 60,711 Managed care services 115 93 341 296 Total Government Business 24,571 21,658 72,164 61,007 IngenioRx Pharmacy products and services 7,249 6,549 21,003 18,630 Other Integrated health services 3,153 2,506 9,083 7,121 Other 212 164 801 436 Total Other 3,365 2,670 9,884 7,557 Eliminations Eliminations (6,054) (5,192) (18,382) (15,173) Total product revenues $ 39,625 $ 35,548 $ 115,993 $ 100,925
Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income	A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Reportable segments’ operating revenue $ 39,625 $ 35,548 $ 115,993 $ 100,925 Net investment income 371 335 1,112 1,026 Net (losses) gains on financial instruments (57) (61) (439) 107 Total revenues $ 39,939 $ 35,822 $ 116,666 $ 102,058
Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income	A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Income before income tax expense $ 2,146 $ 1,996 $ 6,615 $ 6,525 Net investment income (371) (335) (1,112) (1,026) Net losses (gains) on financial instruments 57 61 439 (107) Interest expense 213 201 622 598 Amortization of other intangible assets 225 136 520 306 Loss on extinguishment of debt — — — 5 Reportable segments’ operating gain $ 2,270 $ 2,059 $ 7,084 $ 6,301

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	The information related to our leases is as follows: Balance Sheet Location September 30, 2022 December 31, 2021 Operating Leases Right-of-use assets Other noncurrent assets $ 600 $ 628 Lease liabilities, current Other current liabilities 182 133 Lease liabilities, noncurrent Other noncurrent liabilities 739 864 Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Expense Operating lease expense $ 35 $ 37 $ 100 $ 100 Short-term lease expense 11 10 35 34 Sublease income (1) (1) (3) (3) Total lease expense $ 45 $ 46 $ 132 $ 131 Other information Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 53 $ 53 $ 158 $ 141 Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 23 $ 32 $ 62 $ 192
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows: 2022 (excluding the nine months ended September 30, 2022) $ 54 2023 207 2024 179 2025 142 2026 105 Thereafter 345 Total future minimum payments 1,032 Less imputed interest (111) Total lease liabilities $ 921

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
Goodwill and Other Intangible Assets (Tables)	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment	A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows: Commercial Government IngenioRx Other Total Balance as of January 1, 2021 $ 11,593 $ 8,331 $ 48 $ 1,719 $ 21,691 Acquisitions and adjustments — 2,018 11 508 2,537 Balance as of December 31, 2021 11,593 10,349 59 2,227 24,228 Acquisitions and adjustments 18 126 — 9 153 Balance as of September 30, 2022 $ 11,611 $ 10,475 $ 59 $ 2,236 $ 24,381 Accumulated impairment as of September 30, 2022 $ — $ — $ — $ — $ —
Components Of Other Intangible Assets	The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows: September 30, 2022 December 31, 2021 Gross Accumulated Net Gross Accumulated Net Intangible assets with finite lives: Customer relationships $ 5,791 $ (3,580) $ 2,211 $ 5,598 $ (3,236) $ 2,362 Provider and hospital relationships 326 (142) 184 324 (129) 195 Other 920 (310) 610 610 (141) 469 Total 7,037 (4,032) 3,005 6,532 (3,506) 3,026 Intangible assets with indefinite lives: Blue Cross and Blue Shield and other trademarks 5,991 — 5,991 6,299 — 6,299 State Medicaid licenses 1,540 — 1,540 1,290 — 1,290 Total 7,531 — 7,531 7,589 — 7,589 Other intangible assets $ 14,568 $ (4,032) $ 10,536 $ 14,121 $ (3,506) $ 10,615

Organization (Details)

Organization (Details) medical_member in Millions	Sep. 30, 2022 medical_member county states
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Medical Members \| medical_member	47
Number of counties in the Kansas City area the Company does not serve \| county	30
Number of states in which the Company is licensed to conduct insurance operations \| states	50

Basis of Presentation and Signf

Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Accounting Policies [Line Items]
Customer funds and cash and cash equivalents on deposit for regulatory requirements	$ 291			$ 173
Securities lending transactions, initial collateral percentage value	102%
Premium receivable, allowance for doubtful accounts	$ 140			142
Self-funded receivables, allowance for doubtful accounts	82			50
Allowance for doubtful accounts, other receivables	709			648
Stockholders' equity attributable to parent	35,991			36,060	$ 35,808
Retained Earnings [Member]
Accounting Policies [Line Items]
Stockholders' equity attributable to parent	$ 29,604	$ 28,825	$ 28,058	27,088	$ 26,700	$ 25,874	$ 24,793
Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06 [Member] \| Retained Earnings [Member]
Accounting Policies [Line Items]
Long-term Debt				31
Deferred Tax and Other Liabilities, Noncurrent				(8)
Stockholders' equity attributable to parent				$ (23)

Business Acquisitions Business

Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 1,577
Indefinite-lived Intangible Assets Acquired	20
Goodwill, Acquired During Period	2,531
Goodwill	24,381	$ 24,228	$ 21,691
Integra Managed Care [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	89
Indefinite-lived Intangible Assets Acquired	250
Goodwill, Purchase Accounting Adjustments	13
Goodwill	$ 123

Business Optimization Initiat_3

Business Optimization Initiatives (Employee Termination Costs) (Details) - Employee Severance [Member] $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Optimization Initiatives [Line Items]
Liability for employee terminations costs, beginning	$ 122
Payments	(30)
Liability for employee terminations costs, ending	92
IngenioRx Segment [Member]
Business Optimization Initiatives [Line Items]
Liability for employee terminations costs, beginning	1
Payments	0
Liability for employee terminations costs, ending	1
Other Segment [Member]
Business Optimization Initiatives [Line Items]
Liability for employee terminations costs, beginning	3
Payments	0
Liability for employee terminations costs, ending	3
Government Business Segment [Member]
Business Optimization Initiatives [Line Items]
Liability for employee terminations costs, beginning	57
Payments	(14)
Liability for employee terminations costs, ending	43
Commercial & Specialty Business Segment [Member]
Business Optimization Initiatives [Line Items]
Liability for employee terminations costs, beginning	61
Payments	(16)
Liability for employee terminations costs, ending	$ 45

Investments (Current And Long-T

Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	$ 28,977	$ 26,257
Gross Unrealized Gains	58	830
Gross Unrealized Losses	(2,877)	(182)
Fixed maturities, allowance for credit loss	(10)	(6)
Available-for-sale Securities	26,148	26,899
United States Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	1,673	1,443
Gross Unrealized Gains	0	7
Gross Unrealized Losses	(125)	(18)
Fixed maturities, allowance for credit loss	0	0
Available-for-sale Securities	1,548	1,432
Government Sponsored Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	65	65
Gross Unrealized Gains	0	4
Gross Unrealized Losses	(4)	(1)
Fixed maturities, allowance for credit loss	0	0
Available-for-sale Securities	61	68
Foreign Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	322	353
Gross Unrealized Gains	0	7
Gross Unrealized Losses	(70)	(13)
Fixed maturities, allowance for credit loss	(1)	0
Available-for-sale Securities	251	347
States, Municipalities And Political Subdivisions [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	4,431	5,321
Gross Unrealized Gains	5	310
Gross Unrealized Losses	(355)	(10)
Fixed maturities, allowance for credit loss	0	0
Available-for-sale Securities	4,081	5,621
Corporate Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	13,766	12,044
Gross Unrealized Gains	9	401
Gross Unrealized Losses	(1,560)	(78)
Fixed maturities, allowance for credit loss	(7)	(4)
Available-for-sale Securities	12,208	12,363
Residential Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	4,748	4,059
Gross Unrealized Gains	7	75
Gross Unrealized Losses	(506)	(35)
Fixed maturities, allowance for credit loss	(2)	(2)
Available-for-sale Securities	4,247	4,097
Commercial Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	77	65
Gross Unrealized Gains	0	2
Gross Unrealized Losses	(7)	(3)
Fixed maturities, allowance for credit loss	0	0
Available-for-sale Securities	70	64
Other Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost or Amortized Cost	3,895	2,907
Gross Unrealized Gains	37	24
Gross Unrealized Losses	(250)	(24)
Fixed maturities, allowance for credit loss	0	0
Available-for-sale Securities	$ 3,682	$ 2,907

Investments (Aggregate Fair Val

Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) - Fixed Maturities [Member] $ in Millions	Sep. 30, 2022 USD ($) securities	Dec. 31, 2021 USD ($) securities
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	9,606	3,571
Estimated fair value, less than 12 months	$ 20,511	$ 8,755
Gross unrealized loss, less than 12 months	$ (2,056)	$ (131)
Number of securities, 12 months or greater \| securities	2,444	686
Estimated fair value, 12 months or greater	$ 4,128	$ 985
Gross unrealized loss, 12 months or greater	$ (821)	$ (51)
United States Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	65	51
Estimated fair value, less than 12 months	$ 911	$ 990
Gross unrealized loss, less than 12 months	$ (77)	$ (11)
Number of securities, 12 months or greater \| securities	29	27
Estimated fair value, 12 months or greater	$ 303	$ 176
Gross unrealized loss, 12 months or greater	$ (48)	$ (7)
Government Sponsored Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	40	0
Estimated fair value, less than 12 months	$ 61	$ 0
Gross unrealized loss, less than 12 months	$ (4)	$ 0
Number of securities, 12 months or greater \| securities	1	1
Estimated fair value, 12 months or greater	$ 0	$ 1
Gross unrealized loss, 12 months or greater	$ 0	$ (1)
Foreign Government Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	225	188
Estimated fair value, less than 12 months	$ 169	$ 143
Gross unrealized loss, less than 12 months	$ (34)	$ (8)
Number of securities, 12 months or greater \| securities	151	68
Estimated fair value, 12 months or greater	$ 81	$ 41
Gross unrealized loss, 12 months or greater	$ (36)	$ (5)
States, Municipalities And Political Subdivisions [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	1,964	281
Estimated fair value, less than 12 months	$ 3,602	$ 634
Gross unrealized loss, less than 12 months	$ (314)	$ (9)
Number of securities, 12 months or greater \| securities	139	8
Estimated fair value, 12 months or greater	$ 200	$ 16
Gross unrealized loss, 12 months or greater	$ (41)	$ (1)
Corporate Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	4,322	1,846
Estimated fair value, less than 12 months	$ 10,228	$ 3,310
Gross unrealized loss, less than 12 months	$ (1,165)	$ (57)
Number of securities, 12 months or greater \| securities	1,318	403
Estimated fair value, 12 months or greater	$ 1,679	$ 485
Gross unrealized loss, 12 months or greater	$ (395)	$ (21)
Residential Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	2,035	692
Estimated fair value, less than 12 months	$ 2,949	$ 1,967
Gross unrealized loss, less than 12 months	$ (294)	$ (26)
Number of securities, 12 months or greater \| securities	530	125
Estimated fair value, 12 months or greater	$ 1,182	$ 173
Gross unrealized loss, 12 months or greater	$ (212)	$ (9)
Commercial Mortgage-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	34	2
Estimated fair value, less than 12 months	$ 56	$ 4
Gross unrealized loss, less than 12 months	$ (3)	$ (1)
Number of securities, 12 months or greater \| securities	7	4
Estimated fair value, 12 months or greater	$ 13	$ 8
Gross unrealized loss, 12 months or greater	$ (4)	$ (2)
Other Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Number of securities, less than 12 months \| securities	921	511
Estimated fair value, less than 12 months	$ 2,535	$ 1,707
Gross unrealized loss, less than 12 months	$ (165)	$ (19)
Number of securities, 12 months or greater \| securities	269	50
Estimated fair value, 12 months or greater	$ 670	$ 85
Gross unrealized loss, 12 months or greater	$ (85)	$ (5)

Investments (Amortized Cost And

Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Due in one year or less, Amortized Cost	$ 911
Due after one year through five years, Amortized Cost	7,364
Due after five years through ten years, Amortized Cost	9,535
Due after ten years, Amortized Cost	6,342
Mortgage-backed securities, Amortized Cost	4,825
Available-for-sale securities, Amortized Cost	28,977	$ 26,257
Due in one year or less, Estimated Fair Value	901
Due after one year through five years, Estimated Fair Value	6,871
Due after five years through ten years, Estimated Fair Value	8,467
Due after ten years, Estimated Fair Value	5,592
Mortgage-backed securities, Estimated Fair Value	4,317
Available-for-sale securities, Estimated Fair Value	$ 26,148	$ 26,899

Investments (Current Equity Sec

Investments (Current Equity Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Equity Securities [Line Items]
Equity securities	$ 1,503	$ 1,881
Exchange Traded Funds [Member]
Equity Securities [Line Items]
Equity securities	1,403	1,750
Common Equity Securities [Member]
Equity Securities [Line Items]
Equity securities	5	42
Private Equity Funds [Member]
Equity Securities [Line Items]
Equity securities	$ 95	$ 89

Investments (Net Investment Gai

Investments (Net Investment Gains/Losses) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investment [Line Items]
Net (losses) gains on investments	$ (54)	$ (73)	$ (482)	$ 48
Fixed Maturities [Member]
Investment [Line Items]
Debt Securities, Available-for-sale, Realized Gain	8	30	44	133
Debt Securities, Available-for-sale, Realized Loss	(99)	(8)	(353)	(32)
Impairment (losses) recoveries recognized in income	(5)	0	(25)	1
Debt Securities, Available-for-sale, Realized Gain (Loss)	(96)	22	(334)	102
Equity Securities [Member]
Investment [Line Items]
Unrealized (losses) gains recognized on equity securities still held at the end of the period	(43)	(4)	(192)	4
Net realized gains (losses) recognized on equity securities sold during the period	4	(1)	(20)	(57)
Net losses on equity securities	(39)	(5)	(212)	(53)
Other Investments [Member]
Investment [Line Items]
Gross gains	95	2	126	9
Gross losses	(2)	(93)	(45)	(5)
Impairment (losses) recoveries recognized in income	(12)	1	(17)	(5)
Net losses (gains) on other investments	$ 81	$ (90)	$ 64	$ (1)

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Investments (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Schedule of Investments [Line Items]
Accrued investment income receivable	$ 228		$ 228		$ 205
Fair value of collateral received at time of securities lending transactions	$ 2,841		$ 2,841		$ 2,155
Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned	102%		102%		102%
Fixed maturities, allowance for credit losses	$ (10)		$ (10)		$ (6)
United States Government Securities [Member]
Schedule of Investments [Line Items]
Fixed maturities, allowance for credit losses	0		0		0
Other Securities [Member]
Schedule of Investments [Line Items]
Fixed maturities, allowance for credit losses	0		0		0
Fixed Maturities [Member]
Schedule of Investments [Line Items]
Proceeds from Sale of Available-for-sale Securities	5,281	$ 2,620	15,953	$ 8,570
Overnight and Continuous [Member] \| Cash [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	2,636		2,636		1,874
Overnight and Continuous [Member] \| United States Government Securities [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	180		180		281
Overnight and Continuous [Member] \| Other Securities [Member]
Schedule of Investments [Line Items]
Collateral received for securities loaned, at carrying value	$ 25		$ 25		$ 0

Derivative Financial Instrume_2

Derivative Financial Instruments (Financial Statement Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Gain (Loss) Recognized	$ (3)	$ 12	$ 43	$ 59
Cash Flow Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	$ (231)		$ (231)		$ (239)

Fair Value (Fair Value Measurem

Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 5,794	$ 2,415
Available-for-sale Securities	26,148	26,899
Other invested assets	5,516	5,225
Securities lending collateral	2,841	2,155
Total assets	36,460	33,507
Total liabilities	(70)	(1)
United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	1,548	1,432
Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	61	68
Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	251	347
States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,081	5,621
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	12,208	12,363
Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,247	4,097
Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	70	64
Other Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,682	2,907
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	1,503	1,881
Equity Securities [Member] \| Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	1,403	1,750
Equity Securities [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	5	42
Equity Securities [Member] \| Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	95	89
Other Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,367	5,087
Other Investments [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	149	138
Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	25	19
Derivative liabilities	(70)	(1)
Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	5,794	2,415
Available-for-sale Securities	0	0
Securities lending collateral	0	0
Total assets	7,352	4,311
Total liabilities	0	0
Level I [Member] \| United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Other Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level I [Member] \| Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	1,409	1,758
Level I [Member] \| Equity Securities [Member] \| Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	1,403	1,750
Level I [Member] \| Equity Securities [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	6	8
Level I [Member] \| Equity Securities [Member] \| Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level I [Member] \| Other Investments [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	149	138
Level I [Member] \| Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0	0
Derivative liabilities	0	0
Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Available-for-sale Securities	25,708	26,539
Securities lending collateral	2,841	2,155
Total assets	28,573	28,747
Total liabilities	(70)	(1)
Level II [Member] \| United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	1,548	1,432
Level II [Member] \| Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	61	68
Level II [Member] \| Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	251	347
Level II [Member] \| States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,081	5,621
Level II [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	12,079	12,027
Level II [Member] \| Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	4,247	4,092
Level II [Member] \| Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	70	64
Level II [Member] \| Other Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,371	2,888
Level II [Member] \| Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	(1)	34
Level II [Member] \| Equity Securities [Member] \| Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level II [Member] \| Equity Securities [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	(1)	34
Level II [Member] \| Equity Securities [Member] \| Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level II [Member] \| Other Investments [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Level II [Member] \| Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	25	19
Derivative liabilities	(70)	(1)
Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Available-for-sale Securities	440	360
Securities lending collateral	0	0
Total assets	535	449
Total liabilities	0	0
Level III [Member] \| United States Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] \| Government Sponsored Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] \| Foreign Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] \| States, Municipalities And Political Subdivisions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	129	336
Level III [Member] \| Residential Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	5
Level III [Member] \| Commercial Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0	0
Level III [Member] \| Other Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	311	19
Level III [Member] \| Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	95	89
Level III [Member] \| Equity Securities [Member] \| Exchange Traded Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level III [Member] \| Equity Securities [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	0	0
Level III [Member] \| Equity Securities [Member] \| Private Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	95	89
Level III [Member] \| Other Investments [Member] \| Common Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Level III [Member] \| Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	0	0
Derivative liabilities	$ 0	$ 0

Fair Value (Reconciliation Of T

Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 467	$ 437	$ 449	$ 392
Total gains (losses) recognized in net income	0	6	1	19
Total gains (losses) recognized in accumulated other comprehensive loss	18	(1)	16	4
Purchases	95	37	345	146
Sales	(29)	(1)	(221)	(16)
Settlements	(10)	(47)	(42)	(119)
Transfers into Level III			9
Transfers out of Level III	(6)	(10)	(22)	(5)
Ending balance	535	421	535	421
Change in unrealized gains (losses) included in net income related to assets still held	0	5	1	17
Corporate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	155	351	336	325
Total gains (losses) recognized in net income	0	1	0	2
Total gains (losses) recognized in accumulated other comprehensive loss	1	(1)	(1)	4
Purchases	15	34	40	135
Sales	(26)	0	(201)	(12)
Settlements	(10)	(47)	(42)	(118)
Transfers into Level III			9
Transfers out of Level III	(6)	(4)	(12)	(2)
Ending balance	129	334	129	334
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Residential Mortgage-Backed Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0	2	5	2
Total gains (losses) recognized in net income	0	0	0	0
Total gains (losses) recognized in accumulated other comprehensive loss	0	0	0	0
Purchases	0	0	0	0
Sales	0	0	0	0
Settlements	0	0	0	0
Transfers into Level III			0
Transfers out of Level III	0	(1)	(5)	(1)
Ending balance	0	1	0	1
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Other Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	218	7	19	5
Total gains (losses) recognized in net income	0	0	0	0
Total gains (losses) recognized in accumulated other comprehensive loss	17	0	17	0
Purchases	77	0	281	0
Sales	(1)	0	(1)	0
Settlements	0	0	0	(1)
Transfers into Level III			0
Transfers out of Level III	0	(5)	(5)	(2)
Ending balance	311	2	311	2
Change in unrealized gains (losses) included in net income related to assets still held	0	0	0	0
Equity Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	94	77	89	60
Total gains (losses) recognized in net income	0	5	1	17
Total gains (losses) recognized in accumulated other comprehensive loss	0	0	0	0
Purchases	3	3	24	11
Sales	(2)	(1)	(19)	(4)
Settlements	0	0	0	0
Transfers into Level III			0
Transfers out of Level III	0	0	0	0
Ending balance	95	84	95	84
Change in unrealized gains (losses) included in net income related to assets still held	$ 0	$ 5	$ 1	$ 17

Fair Value (Carrying And Estima

Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	$ 5,516	$ 5,225
Short-term borrowings	265	275
Commercial paper	675	300
Notes	20,163	25,150
Convertible debentures	554	687
Fair Value, Recurring [Member] \| Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	0	0
Commercial paper	0	0
Notes	0	0
Convertible debentures	0	0
Fair Value, Recurring [Member] \| Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	265	275
Commercial paper	675	300
Notes	20,163	25,150
Convertible debentures	554	687
Fair Value, Recurring [Member] \| Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term borrowings	0	0
Commercial paper	0	0
Notes	0	0
Convertible debentures	0	0
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,367	5,087
Short-term borrowings	265	275
Commercial paper	675	300
Notes	22,747	22,384
Convertible debentures	86	72
Other Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,367	5,087
Other Investments [Member] \| Fair Value, Recurring [Member] \| Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	5,367	5,087
Other Investments [Member] \| Fair Value, Recurring [Member] \| Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	0	0
Other Investments [Member] \| Fair Value, Recurring [Member] \| Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other invested assets	$ 0	$ 0

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 533	$ 494	$ 1,557	$ 1,555
Effective tax rate	24.80%	24.70%	23.50%	23.80%
Income taxes receivable	$ 214		$ 214		$ 173

Medical Claims Payable (Reconci

Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Medical Claims Payable [Line Items]
Gross medical claims payable, beginning of period			$ 13,282			$ 11,135	$ 13,282	$ 11,135
Ceded medical claims payable, beginning of period			(21)			(46)	(21)	(46)
Net medical claims payable, beginning of period			13,261			11,089	13,261	11,089
Business combinations and purchase adjustments	$ 133			$ 420			133	420
Current period net incurred medical claims							84,177	74,097
Prior periods redundancies							(901)	(1,822)
Total net incurred medical claims	28,511	$ 27,634	27,131	25,704	$ 23,844	22,727	83,276	72,275
Net payments attributable to current period medical claims							70,453	62,123
Net payments attributable to prior periods medical claims							11,219	8,400
Total net payments							81,672	70,523
Net medical claims payable, end of period	14,998			13,261			14,998	13,261
Ceded medical claims payable, end of period	3			38			3	38
Gross medical claims payable, end of period	15,001			13,299			15,001	13,299
Commercial & Specialty Business Segment [Member]
Medical Claims Payable [Line Items]
Gross medical claims payable, beginning of period			3,847			3,294	3,847	3,294
Ceded medical claims payable, beginning of period			(13)			(13)	(13)	(13)
Net medical claims payable, beginning of period			3,834			3,281	3,834	3,281
Business combinations and purchase adjustments	3			0			3	0
Current period net incurred medical claims							22,049	20,499
Prior periods redundancies							(183)	(496)
Total net incurred medical claims	7,510	7,522	6,834	7,213	6,718	6,072	21,866	20,003
Net payments attributable to current period medical claims							18,604	16,985
Net payments attributable to prior periods medical claims							3,181	2,450
Total net payments							21,785	19,435
Net medical claims payable, end of period	3,918			3,849			3,918	3,849
Ceded medical claims payable, end of period	3			15			3	15
Gross medical claims payable, end of period	3,921			3,864			3,921	3,864
Government Business Segment [Member]
Medical Claims Payable [Line Items]
Gross medical claims payable, beginning of period			9,157			7,646	9,157	7,646
Ceded medical claims payable, beginning of period			(8)			(33)	(8)	(33)
Net medical claims payable, beginning of period			9,149			7,613	9,149	7,613
Business combinations and purchase adjustments	130			375			130	375
Current period net incurred medical claims							60,971	52,422
Prior periods redundancies							(639)	(1,309)
Total net incurred medical claims	20,601	19,788	19,943	18,071	16,723	16,319	60,332	51,113
Net payments attributable to current period medical claims							50,950	44,160
Net payments attributable to prior periods medical claims							7,854	5,781
Total net payments							58,804	49,941
Net medical claims payable, end of period	10,807			9,160			10,807	9,160
Ceded medical claims payable, end of period	0			23			0	23
Gross medical claims payable, end of period	10,807			9,183			10,807	9,183
Other Segment [Member]
Medical Claims Payable [Line Items]
Gross medical claims payable, beginning of period			278			195	278	195
Ceded medical claims payable, beginning of period			0			0	0	0
Net medical claims payable, beginning of period			278			195	278	195
Business combinations and purchase adjustments	0			45			0	45
Current period net incurred medical claims							1,157	1,176
Prior periods redundancies							(79)	(17)
Total net incurred medical claims	400	$ 324	$ 354	420	$ 403	$ 336	1,078	1,159
Net payments attributable to current period medical claims							899	978
Net payments attributable to prior periods medical claims							184	169
Total net payments							1,083	1,147
Net medical claims payable, end of period	273			252			273	252
Ceded medical claims payable, end of period	0			0			0	0
Gross medical claims payable, end of period	$ 273			$ 252			$ 273	$ 252

Medical Claims Payable (Recon_2

Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Reconciliation of net incurred medical claims to benefit expense [Line Items]
Total net incurred medical claims	$ 28,511	$ 27,634	$ 27,131	$ 25,704	$ 23,844	$ 22,727	$ 83,276	$ 72,275
Quality improvement and other claims expense	893	1,143	1,084	941	919	972	3,120	2,832
Benefit expense	29,404	28,777	28,215	26,645	24,763	23,699	86,396	75,107
Commercial & Specialty Business Segment [Member]
Reconciliation of net incurred medical claims to benefit expense [Line Items]
Total net incurred medical claims	7,510	7,522	6,834	7,213	6,718	6,072	21,866	20,003
Government Business Segment [Member]
Reconciliation of net incurred medical claims to benefit expense [Line Items]
Total net incurred medical claims	20,601	19,788	19,943	18,071	16,723	16,319	60,332	51,113
Other Segment [Member]
Reconciliation of net incurred medical claims to benefit expense [Line Items]
Total net incurred medical claims	$ 400	$ 324	$ 354	$ 420	$ 403	$ 336	$ 1,078	$ 1,159

Medical Claims Payable Medical

Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Net medical claims payable, end of period	$ 14,998	$ 13,261		$ 11,089
Ceded medical claims payable end of period	3	21	$ 38	46
Insurance lines other than short duration	241
Gross medical claims payable, end of period	15,242	13,518
Commercial & Specialty Business Segment [Member]
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Net medical claims payable, end of period	3,918	3,834		3,281
Ceded medical claims payable end of period	3	13	15	13
Insurance lines other than short duration	0
Gross medical claims payable, end of period	3,921
Government Business Segment [Member]
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Net medical claims payable, end of period	10,807	9,149		7,613
Ceded medical claims payable end of period	0	8	23	33
Insurance lines other than short duration	241
Gross medical claims payable, end of period	11,048
Other Segment [Member]
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]
Net medical claims payable, end of period	273	278		195
Ceded medical claims payable end of period	0	$ 0	$ 0	$ 0
Insurance lines other than short duration	0
Gross medical claims payable, end of period	$ 273

Medical Claims Payable (Narrati

Medical Claims Payable (Narrative) (Details) $ in Millions	Sep. 30, 2022 USD ($)
Short-Duration Insurance Contract, Accident Year 2020 [Member] \| Commercial & Specialty Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 81
Short-Duration Insurance Contract, Accident Year 2020 [Member] \| Government Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	148
Short-Duration Insurance Contract, Accident Year 2020 [Member] \| Other Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	2
Short-Duration Insurance Contract, Accident Year 2021 [Member] \| Commercial & Specialty Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	388
Short-Duration Insurance Contract, Accident Year 2021 [Member] \| Government Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	508
Short-Duration Insurance Contract, Accident Year 2021 [Member] \| Other Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	14
Short-Duration Insurance Contract, Accident Year 2022 [Member] \| Commercial & Specialty Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	3,449
Short-Duration Insurance Contract, Accident Year 2022 [Member] \| Government Business Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	10,151
Short-Duration Insurance Contract, Accident Year 2022 [Member] \| Other Segment [Member]
Claims Development [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 257

Debt (Convertible Debenture Det

Debt (Convertible Debenture Details) (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Net debt carrying amount	$ 554	$ 687
Convertible Debt [Member]
Debt Instrument [Line Items]
Outstanding principal amount	86
Net debt carrying amount	$ 86
Conversion rate (shares of common stock per $1,000 of principal)	14.2967
Effective conversion price (per $1,000 of principal amount) per share \| $ / shares	$ 69.9462

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
Debt (Narrative) (Details) - USD ($) $ in Millions	Apr. 18, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	May 16, 2022	Apr. 29, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 0	$ 0	$ 0	$ 5
Commercial paper		675		675						$ 300
Stockholders' equity attributable to parent		35,991	35,808	35,991	35,808					36,060
Repayments of Long-term Debt				982	954
Short-term borrowings		265		265						275
Retained Earnings [Member]
Debt Instrument [Line Items]
Stockholders' equity attributable to parent		29,604	$ 26,700	$ 29,604	$ 26,700	$ 28,825			$ 28,058	27,088	$ 25,874	$ 24,793
Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06 [Member] \| Retained Earnings [Member]
Debt Instrument [Line Items]
Long-term Debt										31
Deferred Tax and Other Liabilities, Noncurrent										(8)
Stockholders' equity attributable to parent										(23)
Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Covenant description				Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.
Covenant compliance				As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility.
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Conversion Debt Principal Amount		4		$ 19
Repayments of Long-term Debt		25		132
Subsidiary Credit Facilities [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		200		200
Federal Home Loan Bank Advances [Member]
Debt Instrument [Line Items]
Federal Home Loan Bank, advances, short-term		265		265						275
Surplus Notes [Member]
Debt Instrument [Line Items]
Long-term Debt		25		25						25
Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt		22,722		22,722						22,359
Senior Unsecured Notes [Member] \| Four Point One Zero Percent Due Two Thousand Thirty Two [Member]
Debt Instrument [Line Items]
Debt instrument interest rate								4.10%
Debt Instrument, Face Amount								$ 600
Senior Unsecured Notes [Member] \| Four Point Five Five Zero Due Two Thousand Fifty Two [Member]
Debt Instrument [Line Items]
Debt instrument interest rate								4.55%
Debt Instrument, Face Amount								$ 700
Senior Unsecured Notes [Member] \| Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]
Debt Instrument [Line Items]
Debt instruments, repurchased face amount							$ 850
Debt instrument interest rate							3.125%
Commercial Paper Program
Debt Instrument [Line Items]
Commercial paper authorized		4,000		4,000		$ 3,500
Commercial paper		$ 675		$ 675						$ 300
2021 364-Day Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Description	Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022
2021 364-Day Facility [Member] \| Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity									1,000
5-Year Facility [Member] \| Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 4,000								$ 2,500

Commitments And Contingencies (

Commitments And Contingencies (Details) $ in Millions	9 Months Ended
Commitments And Contingencies (Details) $ in Millions	Sep. 30, 2022 USD ($)
Commitments And Contingencies [Line Items]
Aggregate settlement amount	$ 596
Loss Contingency Accrual, Payments	$ 506
Gross premium tax rate, state of California	2.35%
Long-term purchase commitment, amount	$ 830
Minimum [Member]
Commitments And Contingencies [Line Items]
Aggregate settlement amount	0
Maximum [Member]
Commitments And Contingencies [Line Items]
Aggregate settlement amount	$ 250
BCBS Antitrust Litigation [Member]
Commitments And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number	8,000
Anthem, Inc. v. Express Scripts, Inc. [Member]
Commitments And Contingencies [Line Items]
Proceeds originally received at time of divestiture	$ 4,675
Anthem, Inc. v. Express Scripts, Inc. [Member] \| Damages for Pharmacy Pricing [Member]
Commitments And Contingencies [Line Items]
Approximate amount of damages sought for breaches	14,800
Anthem, Inc. v. Express Scripts, Inc. [Member] \| Damages for Operational Breaches [Member]
Commitments And Contingencies [Line Items]
Approximate amount of damages sought for breaches	$ 158

Capital Stock (Summary of Cash

Capital Stock (Summary of Cash Dividend Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]
Declaration date	Jul. 19, 2022	Apr. 19, 2022	Jan. 25, 2022	Jul. 20, 2021	Apr. 20, 2021	Jan. 26, 2021
Record date	Sep. 09, 2022	Jun. 10, 2022	Mar. 10, 2022	Sep. 10, 2021	Jun. 10, 2021	Mar. 10, 2021
Payment date	Sep. 23, 2022	Jun. 24, 2022	Mar. 25, 2022	Sep. 24, 2021	Jun. 25, 2021	Mar. 25, 2021
Cash dividends per share	$ 1.28	$ 1.28	$ 1.28	$ 1.13	$ 1.13	$ 1.13
Total payment	$ 306	$ 309	$ 309	$ 276	$ 278	$ 277	$ 924	$ 831

Capital Stock (Summary of Share

Capital Stock (Summary of Share Repurchases) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity, Class of Treasury Stock [Line Items]
Shares repurchased							3.7	3.9
Average price per share							$ 473.36	$ 356.43
Aggregate cost	$ 579	$ 624	$ 545	$ 451	$ 480	$ 447	$ 1,748	$ 1,378
Authorization remaining at the end of the period	$ 2,444			$ 4,714			$ 2,444	$ 4,714

Capital Stock (Summary of Stock

Capital Stock (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Number of Shares [Roll Forward]
Outstanding at beginning of period, Number of Shares \| shares	2.9
Granted, Number of Shares \| shares	0.5
Exercised, Number of Shares \| shares	(0.4)
Forfeited or expired, Number of Shares \| shares	(0.1)
Outstanding at end of period, Number of Shares \| shares	2.9
Exercisable at end of period, Number of Shares \| shares	1.7
Weighted-Average Option Price Per Share [Roll Forward]
Outstanding at beginning of period, Weighted-Average Option Price per Share \| $ / shares	$ 255.50
Granted, Weighted-Average Option Price per Share \| $ / shares	452.34
Exercised, Weighted-Average Option Price per Share \| $ / shares	243.39
Forfeited or expired, Weighted-Average Option Price per Share \| $ / shares	339.52
Outstanding at end of period, Weighted-Average Option Price per Share \| $ / shares	291.95
Exercisable at end of period, Weighted-Average Option Price per Share \| $ / shares	$ 239.27
Outstanding at end of period, Weighted-Average Remaining Contractual Life	6 years 6 months 21 days
Exercisable at end of period, Weighted-Average Remaining Contractual Life	5 years 4 months 6 days
Outstanding at end of period, Aggregate Intrinsic Value \| $	$ 477
Exercisable at end of period, Aggregate Intrinsic Value \| $	$ 370

Capital Stock (Nonvested Restri

Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) - $ / shares shares in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Restricted Stock Shares and Units [Roll Forward]
Nonvested at Beginning Balance, Restricted Stock Shares and Units	1.3
Granted, Restricted Stock Shares and Units	0.6
Vested, Restricted Stock Shares And Units	(0.6)
Forfeited, Restricted Stock Shares And Units	(0.1)
Nonvested at Ending Balance, Restricted Stock Shares and Units	1.2
Weighted-Average Grant Date Fair Value Per Share [Roll Forward]
Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share	$ 299.65
Granted, Weighted-Average Grant Date Fair Value per Share	453.16	$ 315.54
Vested, Weighted-Average Grant Date Fair Value per Share	301.44
Forfeited, Weighted-Average Grant Date Fair Value per Share	345.25
Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share	$ 356.33

Capital Stock (Fair Values of O

Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]
Risk-free interest rate	1.97%	1.44%
Volatility factor	29%	30%
Quarterly dividend yield	0.282%	0.36%
Weighted-average expected life (years)	5 years 1 month 6 days	5 years 6 months

Capital Stock (Schedule Of Weig

Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]
Options granted during the period	$ 116.85	$ 79.51
Restricted stock awards granted during the period	$ 453.16	$ 315.54

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended						9 Months Ended
	Oct. 18, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Jan. 26, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Dividends Payable, Date to be Paid		Sep. 23, 2022	Jun. 24, 2022	Mar. 25, 2022	Sep. 24, 2021	Jun. 25, 2021	Mar. 25, 2021
Dividends Payable, Date of Record		Sep. 09, 2022	Jun. 10, 2022	Mar. 10, 2022	Sep. 10, 2021	Jun. 10, 2021	Mar. 10, 2021
Increase In Stock Repurchase Program Authorization									$ 5,000
Subsequent Event [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Dividends Payable, Amount Per Share	$ 1.28
Dividends Payable, Date to be Paid	Dec. 21, 2022
Dividends Payable, Date of Record	Dec. 05, 2022
2022 to 2024 \| Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								0.2

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Loss, Beginning Balance	$ (2,149)		$ (178)	$ (17)		$ 150	$ (178)	$ 150
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	(639)			(97)			(2,630)	(284)
Other comprehensive loss attributable to noncontrolling interests	3			1			11	1
Cash flow hedges, holding gain (loss), net of tax	2			4			8	10
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	(7)			(8)			(23)	(26)
Foreign currency translation adjustment, net of tax	(7)			(1)			(15)	(7)
Other Comprehensive Income (Loss), Net of Tax	(638)	$ (916)	(1,063)	(87)	$ 180	(347)	(2,617)	(254)
Accumulated Other Comprehensive Loss, Ending Balance	(2,784)	(2,149)		(103)	(17)		(2,784)	(103)
Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent	198			27			815	81
Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest	(1)			0			(4)	(1)
Net unrealized investment (losses) gains
AOCI, Debt Securities, Beginning Balance	(1,489)		494	762		949	494	949
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	(719)			(80)			(2,914)	(203)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	80			(17)			284	(81)
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	(639)			(97)			(2,630)	(284)
Other comprehensive loss attributable to noncontrolling interests	3			1			11	1
AOCI, Debt Securities, Ending Balance	(2,125)	(1,489)		666	762		(2,125)	666
Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit	220			25			896	71
Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense	(21)			5			(75)	21
Non-credit components of impairments on investments [Member]
Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities	(2)		0	0		(2)	0	(2)
Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities	(1)			(1)			(3)	1
AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance	(3)	(2)		(1)	0		(3)	(1)
Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)	0			0			1	(1)
Net cash flow hedges
AOCI, Cash Flow Hedge, Beginning Balance	(233)		(239)	(244)		(250)	(239)	(250)
Cash flow hedges, holding gain (loss), net of tax	2			4			8	10
AOCI, Cash Flow Hedge, Ending Balance	(231)	(233)		(240)	(244)		(231)	(240)
Cash flow hedges, holding gain (loss), tax (expense) benefit	0			0			(2)	(2)
Pension and other postretirement benefits
AOCI, Defined Benefit Plan, Beginning Balance	(413)		(429)	(534)		(552)	(429)	(552)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	7			8			23	26
AOCI, Defined Benefit Plan, Ending Balance	(406)	(413)		(526)	(534)		(406)	(526)
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense	(3)			(4)			(9)	(10)
Foreign currency translation adjustments
AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance	(12)		$ (4)	(1)		$ 5	(4)	5
Foreign currency translation adjustment, net of tax	(7)			(1)			(15)	(7)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance	(19)	$ (12)		(2)	$ (1)		(19)	(2)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit	$ 2			$ 1			$ 4	$ 2

Earnings Per Share (Denominator

Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Denominator for basic earnings per share - weighted-average shares	239.6	243.4	240.5	244.3
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures	2.6	2.6	2.8	2.9
Denominator for diluted earnings per share	242.2	246	243.3	247.2

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive	0.5	0	0.4	0.3
Restricted stock units issued under stock incentive plan			0.6
2022 to 2024 [Member]
Restricted stock units issued under stock incentive plan	0		0.6
Restricted stock units excluded from the denominator for diluted earnings per share	0		0.2
2021 to 2023 [Member]
Restricted stock units issued under stock incentive plan		0.1		1
Restricted stock units excluded from the denominator for diluted earnings per share		0		0.3

Segment Information (Financial

Segment Information (Financial Data By Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Reportable segments operating revenues	$ 39,625	$ 35,548	$ 115,993	$ 100,925
Operating gain (loss)	2,270	2,059	7,084	6,301
Commercial & Specialty [Member]
Segment Reporting Information [Line Items]
Operating gain (loss)	785	620	2,673	2,679
Government Business [Member]
Segment Reporting Information [Line Items]
Operating gain (loss)	868	967	2,653	2,313
IngenioRx Segment [Member]
Segment Reporting Information [Line Items]
Operating gain (loss)	516	445	1,393	1,257
Other [Member]
Segment Reporting Information [Line Items]
Operating gain (loss)	101	27	365	52
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	(6,054)	(5,192)	(18,382)	(15,173)
Unaffiliated
Segment Reporting Information [Line Items]
Reportable segments operating revenues	39,625	35,548	115,993	100,925
Unaffiliated \| Commercial & Specialty [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	10,494	9,863	31,324	28,904
Unaffiliated \| Government Business [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	24,571	21,658	72,164	61,007
Unaffiliated \| IngenioRx Segment [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	3,971	3,369	10,838	9,131
Unaffiliated \| Other [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	589	658	1,667	1,883
Affiliated [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	0	0	0	0
Affiliated [Member] \| Commercial & Specialty [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues		0	0	0
Affiliated [Member] \| Government Business [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues		0	0	0
Affiliated [Member] \| IngenioRx Segment [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	3,278	3,180	10,165	9,499
Affiliated [Member] \| Other [Member]
Segment Reporting Information [Line Items]
Reportable segments operating revenues	$ 2,776	$ 2,012	$ 8,217	$ 5,674

Segment Information Segment Inf

Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	$ 39,625	$ 35,548	$ 115,993	$ 100,925
Commercial & Specialty Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	10,494	9,863	31,324	28,904
Government Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	24,571	21,658	72,164	61,007
Other Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	3,365	2,670	9,884	7,557
Segment Eliminations [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	(6,054)	(5,192)	(18,382)	(15,173)
Managed Care Products [Member] \| Commercial & Specialty Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	8,478	8,005	25,500	23,481
Managed Care Products [Member] \| Government Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	24,456	21,565	71,823	60,711
Managed Care Services [Member] \| Commercial & Specialty Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	1,610	1,489	4,618	4,291
Managed Care Services [Member] \| Government Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	115	93	341	296
Dental Vision Products And Services [Member] \| Commercial & Specialty Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	360	342	1,075	1,013
Other Products [Member] \| Commercial & Specialty Business Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	46	27	131	119
Other Products [Member] \| Other Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	212	164	801	436
Pharmacy products and services [Member] \| IngenioRx Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	7,249	6,549	21,003	18,630
Integrated health services \| Other Segment [Member]
Major Product Revenue By Segment [Line Items]
Insurance Services Revenue	$ 3,153	$ 2,506	$ 9,083	$ 7,121

Segment Information (Reconcilia

Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting [Abstract]
Reportable segments operating revenues	$ 39,625	$ 35,548	$ 115,993	$ 100,925
Net investment income	371	335	1,112	1,026
Net (losses) gains on financial instruments	(57)	(61)	(439)	107
Total revenues	$ 39,939	$ 35,822	$ 116,666	$ 102,058

Segment Information (Reconcil_2

Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting [Abstract]
Income before income tax expense	$ 2,146	$ 1,996	$ 6,615	$ 6,525
Net investment income	(371)	(335)	(1,112)	(1,026)
Net losses (gains) on financial instruments	57	61	439	(107)
Interest expense	213	201	622	598
Amortization of other intangible assets	225	136	520	306
Loss on extinguishment of debt	0	0	0	5
Reportable segments operating gain	$ 2,270	$ 2,059	$ 7,084	$ 6,301

Segment Information Segment I_2

Segment Information Segment Information (Narrative) (Details)	9 Months Ended
	Sep. 30, 2022 segment
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of Reportable Segments	4

Leases (Lease and Other Informa

Leases (Lease and Other Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Operating Lease, Right-of-Use Asset	$ 600		$ 600		$ 628
Operating Lease, Liability, Current	182		182		133
Operating Lease, Liability, Noncurrent	739		739		$ 864
Operating Lease, Cost	35	$ 37	100	$ 100
Short-term Lease, Cost	11	10	35	34
Sublease Income	(1)	(1)	(3)	(3)
Lease, Cost	45	46	132	131
Operating Lease, Payments	53	53	158	141
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 23	$ 32	$ 62	$ 192
Balance sheet location of operating lease right-of-use assets	Other noncurrent assets		Other noncurrent assets		Other noncurrent assets
Balance sheet location of current operating lease liabilities	Other current liabilities		Other current liabilities		Other current liabilities
Balance sheet location of noncurrent operating lease liabilities	Other noncurrent liabilities		Other noncurrent liabilities		Other noncurrent liabilities

Leases (Reconciliation of Futur

Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) $ in Millions	Sep. 30, 2022 USD ($)
Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract]
Operating lease payments, 2022; excluding the nine months ended September 30, 2022	$ 54
Operating lease payments, 2023	207
Operating lease payments, 2024	179
Operating lease payments, 2025	142
Operating lease payments, 2026	105
Operating lease payments, Thereafter	345
Total future minimum payments	1,032
Imputed Interest, Leases	(111)
Operating Lease Liabilities	$ 921

Leases (Narrative) (Details)

Leases (Narrative) (Details)	Sep. 30, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	7 years	7 years
Weighted Average Discount Rate, Percent	2.79%	2.69%
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	12 years

Goodwill And Other Intangible_3

Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2021	Sep. 30, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 21,691	$ 24,228	$ 21,691
Goodwill, Period Increase (Decrease)		153	2,537
Goodwill, Ending Balance		24,381	24,228
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022		0
Commercial & Specialty Business Segment [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	11,593	11,593	11,593
Goodwill, Period Increase (Decrease)	0	18
Goodwill, Ending Balance		11,611	11,593
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022		0
Government Business Segment [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	8,331	10,349	8,331
Goodwill, Period Increase (Decrease)		126	2,018
Goodwill, Ending Balance		10,475	10,349
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022		0
IngenioRx Segment [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	48	59	48
Goodwill, Period Increase (Decrease)		0	11
Goodwill, Ending Balance		59	59
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022		0
Other Segment [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 1,719	2,227	1,719
Goodwill, Period Increase (Decrease)		9	508
Goodwill, Ending Balance		2,236	$ 2,227
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022		$ 0

Goodwill And Other Intangible_4

Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Intangible Assets [Line Items]
Gross Carrying Amount, Finite Lived Intangibles	$ 7,037	$ 6,532
Accumulated Amortization, Finite-Lived Intangible Assets	(4,032)	(3,506)
Net Carrying Amount, Finite-Lived Intangible Assets	3,005	3,026
Gross Carrying Amount, Indefinite-Lived Intangible Assets	7,531	7,589
Net Carrying Amount, Indefinite-Lived Intangible Assets	7,531	7,589
Gross Carrying Amount, Total Intangible Assets	14,568	14,121
Accumulated Amortization, Total Intangible Assets	(4,032)	(3,506)
Net Carrying Amount, Total Intangible Assets	10,536	10,615
Blue Cross And Blue Shield And Other Trademarks [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-Lived Intangible Assets	5,991	6,299
Net Carrying Amount, Indefinite-Lived Intangible Assets	5,991	6,299
State Medicaid Licenses [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-Lived Intangible Assets	1,540	1,290
Net Carrying Amount, Indefinite-Lived Intangible Assets	1,540	1,290
Customer Relationships [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, Finite Lived Intangibles	5,791	5,598
Accumulated Amortization, Finite-Lived Intangible Assets	(3,580)	(3,236)
Net Carrying Amount, Finite-Lived Intangible Assets	2,211	2,362
Provider And Hospital Relationships [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, Finite Lived Intangibles	326	324
Accumulated Amortization, Finite-Lived Intangible Assets	(142)	(129)
Net Carrying Amount, Finite-Lived Intangible Assets	184	195
Other [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, Finite Lived Intangibles	920	610
Accumulated Amortization, Finite-Lived Intangible Assets	(310)	(141)
Net Carrying Amount, Finite-Lived Intangible Assets	$ 610	$ 469

Goodwill And Other Intangible_5

Goodwill And Other Intangible Assets (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Period Increase	$ 308
Indefinite-Lived Intangible Assets, Period Decrease	308
Finite-Lived Intangible Asset, Expected Amortization, 2022	748
Finite-Lived Intangible Asset, Expected Amortization, 2023	735
Finite-Lived Intangible Asset, Expected Amortization, 2024	370
Finite-Lived Intangible Asset, Expected Amortization, 2025	311
Finite-Lived Intangible Asset, Expected Amortization, 2026	258
Finite-Lived Intangible Asset, Expected Amortization, 2027	$ 219